ThisiscontentfromElsevier'sDrugInformation

    Pitolisant

    Learn more about Elsevier's Drug Information today! Get the drug data and decision support you need, including TRUE Daily Updates™ including every day including weekends and holidays.

    Dec.05.2024

    Pitolisant

    Indications/Dosage

    Labeled

    • cataplexy
    • narcolepsy

    Off-Label

      † Off-label indication

      For the treatment of excessive daytime sleepiness or cataplexy in patients with narcolepsy

      Oral dosage

      Adults

      Initially, 8.9 mg PO once daily in the morning upon waking for 1 week. Then, increase dosage to 17.8 mg PO once daily for 1 week. After that, the dose may be adjusted based on efficacy response and tolerability. Max: 35.6 mg/day PO; limit to 17.8 mg/day PO in CYP2D6 poor metabolizers. Up to 8 weeks may be necessary for clinical response. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions.[64562]

      for the treatment of excessive daytime sleepiness in pediatric patients with narcolepsy

      Oral dosage

      Children and Adolescents 6 to 17 years weighing 40 kg or more

      Initially, 4.45 mg PO once daily in the morning upon waking for 1 week. Then, increase dosage to 8.9 mg PO once daily for 1 week. After that, increase dosage to 17.8 mg PO once daily for 1 week. Dosage may be increased at week 4 to 35.6 mg PO once daily. Max: 35.6 mg/day PO; limit to 17.8 mg/day PO in CYP2D6 poor metabolizers. Up to 8 weeks may be necessary for clinical response. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions.[64562]

      Children and Adolescents 6 to 17 years weighing less than 40 kg

      Initially, 4.45 mg PO once daily in the morning upon waking for 1 week. Then, increase dosage to 8.9 mg PO once daily for 1 week. After that, increase dosage to 17.8 mg PO once daily. Max: 17.8 mg/day PO; limit to 8.9 mg/day PO in CYP2D6 poor metabolizers. Up to 8 weeks may be necessary for clinical response. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions.[64562]

      Therapeutic Drug Monitoring

      Maximum Dosage Limits

      • Adults

        35.6 mg/day PO.

      • Geriatric

        35.6 mg/day PO.

      • Adolescents

        weighing 40 kg or more: 35.6 mg/day PO

        weighing less than 40 kg: 17.8 mg/day PO

      • Children

        6 to 12 years weighing 40 kg or more: 35.6 mg/day PO

        6 to 12 years weighing less than 40 kg: 17.8 mg/day PO

        1 to 5 years: Safety and efficacy have not been established.

      • Infants

        Safety and efficacy have not been established.

      Patients with Hepatic Impairment Dosing

      Adults

      Mild hepatic impairment (Child-Pugh A): No dosage adjustment needed.

      Moderate hepatic impairment (Child-Pugh B): 8.9 mg PO once daily initially, then increase after 14 days to a maximum of 17.8 mg PO once daily.

      Severe hepatic impairment (Child-Pugh C): Use is contraindicated.[64562]

       

      Pediatrics (6 to 17 years)

      Mild hepatic impairment (Child-Pugh A): No dosage adjustment needed.

      Moderate hepatic impairment (Child-Pugh B):

      Weighing 40 kg or more: 4.45 mg PO once daily initially, then increase after 14 days to 8.9 mg PO once daily. May increase after another 14 days to a maximum of 17.8 mg PO once daily.

      Weighing less than 40 kg: 4.45 mg PO once daily initially, then increase after 14 days to a maximum of 8.9 mg PO once daily.

      Severe hepatic impairment (Child-Pugh C): Use is contraindicated.[64562]

      Patients with Renal Impairment Dosing

      Adults

      eGFR 60 mL/minute/1.73 m2 or more (Mild renal impairment): No dose adjustment needed.

      eGFR 15 to 59 mL/minute/1.73 m2 (Moderate to Severe renal impairment): 8.9 mg PO once daily initially, then increase dose after 7 days to a maximum of 17.8 mg PO once daily.

      eGFR less than 15 mL/minute/1.73 m2: Use is not recommended in end-stage renal disease (ESRD); no studies are available in these patients.[64562]

       

      Pediatrics (6 to 17 years)

      eGFR 60 mL/minute/1.73 m2 or more (Mild renal impairment): No dose adjustment needed.

      eGFR 15 to 59 mL/minute/1.73 m2 (Moderate to Severe renal impairment):

      Weighing 40 kg or more: 4.45 mg PO once daily initially, then increase dose after 7 days to 8.9 mg PO once daily. May increase after another 7 days to a maximum of 17.8 mg PO once daily.

      Weighing less than 40 kg: 4.45 mg PO once daily initially, then increase dose after 7 days to a maximum of 8.9 mg PO once daily.

      eGFR less than 15 mL/minute/1.73 m2: Use is not recommended in end-stage renal disease (ESRD); no studies are available in these patients.[64562]

      † Off-label indication
      Revision Date: 12/05/2024, 02:07:00 AM

      References

      64562 - Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2024 Jun.

      How Supplied

      Pitolisant Oral tablet

      Wakix 4.45mg Tablet (72028-0045) (Harmony Biosciences, LLC) nullWakix 4.45mg Tablet package photo

      Pitolisant Oral tablet

      Wakix 17.8mg Tablet (72028-0178) (Harmony Biosciences, LLC) nullWakix 17.8mg Tablet package photo

      Description/Classification

      Description

      Pitolisant is an oral histamine-3 (H3) receptor antagonist/inverse agonist, the first in its class. Pitolisant is indicated for the treatment of excessive daytime sleepiness (EDS) in adults and pediatric patients 6 years and older with narcolepsy. It is also approved for treatment of cataplexy in adult patients with narcolepsy. The efficacy of pitolisant for the treatment of EDS was established in 2 placebo-controlled, active control trials of 8 weeks duration. In both trials, pitolisant-treated patients had significantly improved EDS during activities of daily living as measured using the least-squares mean final Epworth Sleepiness Scale (ESS) vs. ESS scores for patients receiving placebo. The use of pitolisant in pediatric patients was established in a placebo-controlled, 8-week trial of 110 patients with narcolepsy and a Pediatric Daytime Sleepiness Scale (PDSS) score of 15 or more. Patients receiving pitolisant had a statistically significant improvement in the least squares mean change from baseline to end of treatment in final PDSS total score compared to placebo (-3.41 points; 95% CI: -5.52, -1.31). During studies for cataplexy, treated patients had a significant change in the geometric mean number of cataplexy attacks per week from baseline vs. placebo. The drug may cause QT prolongation and it is contraindicated in patients with severe hepatic impairment. Pitolisant was FDA approved in August 2019.[64562]

      Classifications

      • Central and Peripheral Nervous System
        • Psychoanaleptics Excluding Anti-obesity Agents
          • Narcolepsy Agents
            • Histamine-Receptor Modulators
      Revision Date: 12/05/2024, 02:07:00 AM

      References

      64562 - Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2024 Jun.

      Administration Information

      General Administration Information

      For storage information, see the specific product information within the How Supplied section.

      Route-Specific Administration

      Oral Administration

      • Administer each dose in the morning upon patient wakening.
      • If a dose is missed, skip the missed dose and administer the next dose the following day in the morning upon wakening.[64562]

      Clinical Pharmaceutics Information

      From Trissel's 2‚Ñ¢ Clinical Pharmaceutics Database
        Revision Date: 12/05/2024, 02:07:00 AM

        References

        64562 - Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2024 Jun.

        Adverse Reactions

        Mild

        • abdominal pain
        • abnormal dreams
        • anxiety
        • arthralgia
        • back pain
        • carpal tunnel syndrome
        • dizziness
        • fatigue
        • headache
        • infection
        • insomnia
        • irritability
        • musculoskeletal pain
        • myalgia
        • nausea
        • nightmares
        • pharyngitis
        • pruritus
        • rash
        • rhinitis
        • sinusitis
        • urticaria
        • weight gain
        • xerostomia

        Moderate

        • atopic dermatitis
        • cataplexy
        • depression
        • hallucinations
        • migraine
        • QT prolongation
        • sinus tachycardia
        • sleep paralysis

        Severe

        • anaphylactoid reactions
        • seizures
        • suicidal ideation

        In placebo-controlled trials of pitolisant in patients with narcolepsy with and without cataplexy, nausea was a common adverse reaction that occurred in 6% of pitolisant-treated patients compared to 3% of placebo-treated patients. Other gastrointestinal adverse reactions that occurred more frequently with pitolisant treatment than placebo treatment include abdominal pain including abdominal discomfort (3%), decreased appetite (3%), and xerostomia (2%). Weight gain has been observed during postmarketing experience.[64562]

        In placebo-controlled trials of pitolisant in adult patients with narcolepsy with and without cataplexy, insomnia (inclusive of initial and middle insomnia, insomnia, and poor quality sleep) was a common adverse reaction that occurred in 6% of pitolisant-treated patients compared to 2% of placebo-treated patients. Insomnia was also reported in 7% of pediatric patients in clinical trials. Anxiety (inclusive of nervousness, stress, stress at work, and anxiety) occurred in 5% of pitolisant-treated adult patients compared to 1% of placebo-treated patients. Hallucinations (inclusive of visual hallucination, hypnagogic hallucination, and hallucinations) occurred in 3% of pitolisant-treated adult patients compared to no placebo-treated patients. Sleep disturbances (inclusive of dyssomnia, sleep disorder, sleep paralysis, and sleep talking) occurred in 3% of pitolisant-treated adult patients compared to 2% of placebo-treated patients. Other adverse reactions that occurred more frequently with pitolisant treatment than placebo treatment include irritability (3%) and cataplexy (2%). Abnormal behavior, abnormal dreams, anhedonia, bipolar disorder, depression, depressed mood, nightmares, unspecified sleep disorder, suicide attempt, and suicidal ideation have been observed during postmarketing experience.[64562]

        In placebo-controlled trials of pitolisant in patients with narcolepsy with and without cataplexy, headache was a common adverse reaction that occurred in 18% of pitolisant-treated adult patients compared to 15% of placebo-treated patients. Headache was also one of the most common adverse reactions reported in a pediatric clinical trial, affecting 19% of patients. Cluster headache, migraine, headache, premenstrual headache, and tension headaches were observed. Epilepsy, dizziness, and seizures have been observed during postmarketing experience.[64562]

        In placebo-controlled trials of pitolisant in patients with narcolepsy with and without cataplexy, musculoskeletal pain (inclusive of arthralgia, back pain, carpal tunnel syndrome, limb discomfort, myalgia, neck pain, osteoarthritis, musculoskeletal pain, extremity pain, and sciatica) occurred in 5% of pitolisant-treated patients and at incidences higher than with placebo.[64562]

        In placebo-controlled trials of pitolisant in patients with narcolepsy with and without cataplexy, upper respiratory tract infections, (inclusive of pharyngitis, rhinitis, sinusitis, upper respiratory tract inflammation, upper respiratory tract infection, and viral upper respiratory tract infection) occurred in 5% of pitolisant-treated patients and at rates higher than with placebo.[64562]

        In placebo-controlled trials of pitolisant in patients with narcolepsy with and without cataplexy, rash (inclusive of eczema or atopic dermatitis, rash, erythema migrans, and urticaria) occurred in 2% of pitolisant-treated patients and at incidence rates higher than with placebo. Hypersensitivity (anaphylaxis, anaphylactoid reactions) and pruritus have been observed during postmarketing experience.[64562]

        Fatigue has been observed during postmarketing experience with pitolisant.[64562]

        Revision Date: 12/05/2024, 02:07:00 AM

        References

        64562 - Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2024 Jun.

        Contraindications/Precautions

        Absolute contraindications are italicized.

        • apheresis
        • AV block
        • bradycardia
        • breast-feeding
        • cardiac arrhythmias
        • cardiomyopathy
        • celiac disease
        • congenital long QT syndrome
        • contraception requirements
        • females
        • fever
        • geriatric
        • heart failure
        • hepatic disease
        • human immunodeficiency virus (HIV) infection
        • hyperparathyroidism
        • hypocalcemia
        • hypokalemia
        • hypomagnesemia
        • hypothermia
        • hypothyroidism
        • myocardial infarction
        • pheochromocytoma
        • poor metabolizers
        • pregnancy
        • QT prolongation
        • renal failure
        • renal impairment
        • rheumatoid arthritis
        • sickle cell disease
        • sleep deprivation
        • stroke
        • systemic lupus erythematosus

        Pitolisant is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported with use of the drug.[64562]

        Pitolisant is contraindicated in patients with severe hepatic impairment (Child-Pugh C). Pitolisant has not been studied in this population. Pitolisant is extensively metabolized by the liver, and a significant increase in drug exposure occurs in patients with moderate hepatic disease (Child-Pugh B). Specific dosage adjustments are available for patients with moderate hepatic impairment. Monitor hepatic function in patients and adjust the dosage as necessary. No dosage adjustment is recommended in patients with mild hepatic impairment (Child-Pugh A). Dosage reduction is recommended in patients known to be CYP2D6 poor metabolizers (CYP2D6 PMs) because these patients have higher pitolisant concentrations than normal CYP2D6 metabolizers.[64562]

        Pitolisant use is not recommended in patients with end-stage renal disease (i.e., renal failure; eGFR less than 15 mL/minute/1.73 m2), as pitolisant has not been studied in this population. Specific dosage adjustments are available for patients with moderate (eGFR 30 to 59 mL/minute/1.73 m2) or severe renal impairment (eGFR 15 to 29 mL/minute/1.73 m2). No dosage adjustment is needed for patients with mild renal impairment.[64562]

        Pitolisant prolongs the QT interval. Avoid the use of pitolisant in patients with known QT prolongation, receiving medications known to prolong the QT interval, with a history of cardiac arrhythmias, or who have other conditions that may increase the risk of the occurrence of torsade de pointes or sudden death (including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval such as congenital long QT syndrome). Use pitolisant with caution in patients with conditions that may increase the risk of QT prolongation including bradycardia, AV block, heart failure, stress-related cardiomyopathy, myocardial infarction, stroke, hypocalcemia, or in patients receiving medications known to cause electrolyte imbalances. Females, geriatric patients, patients with sleep deprivation, pheochromocytoma, sickle cell disease, hypothyroidism, hyperparathyroidism, hypothermia, systemic inflammation (e.g., human immunodeficiency virus (HIV) infection, fever, and some autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus (SLE), and celiac disease) and patients undergoing apheresis procedures (e.g., plasmapheresis [plasma exchange], cytapheresis) may also be at increased risk for QT prolongation. The risk of QT prolongation may be greater in patients with renal or hepatic impairment due to a decrease in drug elimination with a subsequent increase in drug exposure. A QTc increase of 4.2 milliseconds occurred at the highest recommended dosage of pitolisant (35.6 mg daily). Exposures 3.8-fold higher than that achieved at the highest recommended dose increased mean QTc 16 milliseconds.[28432] [28457] [56592] [65180] [64562]

        There are no adequate data on the developmental risk associated with pitolisant use during human pregnancy. Available case reports from clinical trials and postmarketing reports with pitolisant use in pregnant women have not determined a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproductive studies, administration of pitolisant during organogenesis caused maternal and embryofetal toxicity in rats and rabbits at doses 13 or greater and 4 times or greater the maximum recommended human dose (MRHD) of 35.6 mg based on mg/square meter body surface area, respectively. The no observed adverse effect dose for maternal toxicity and embryofetal development were 2 and 4 times the MRHD based on body surface area, respectively. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to pitolisant during pregnancy. To enroll or obtain information, patients can call 1-800-833-7460. The effects of pitolisant during labor and obstetric delivery are unknown.[64562]

        Contraception requirements are suggested for pitolisant. Pitolisant may reduce the effectiveness of hormonal contraceptives. Female patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with pitolisant and for at least 21 days after discontinuing treatment.[64562]

        Use pitolisant with caution during lactation; consider the developmental and health benefits of breast-feeding along with the mother's clinical need for pitolisant and any potential adverse effects on the breastfed infant from pitolisant or the underlying maternal condition. Pitolisant was found to pass into breast milk at low levels in an open-label study of 8 healthy lactating women who were 11 to 96 weeks postpartum. The concentration of pitolisant was evaluated in breast milk samples collected over 24 hours and serum samples were collected over 120 hours after a single dose of 35.6 mg of pitolisant was administered. Approximately 50% of the amount of pitolisant measured in breast milk occurred during the first 4 hours post dose. Based on the study, the mean infant dose was 0.009 mg/day, less than 1% of the maternal weight-adjusted dose. There are no data on the effects of pitolisant on the breastfed infant or the effect of pitolisant on milk production.[64562]

        Revision Date: 12/05/2024, 02:07:00 AM

        References

        28432 - Roden, DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004;350:1013-22.28457 - Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881-908.56592 - van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70(1):16-23.64562 - Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2024 Jun.65180 - Woosley RL, Heise CW, Gallo T, et al. QTFactors List. Oro Valley, AZ: AZCERT, Inc.; Accessed March 31, 2020. Available on the World Wide Web at: https://crediblemeds.org/ndfa-list/

        Mechanism of Action

        Pitolisant is a selective antagonist/inverse agonist of the histamine-3 (H3) receptor. HIstamine H3 receptors are mainly located in the brain. Activation of histaminergic neurons increases histamine release that promotes wakefulness, attention, and memory. Pitolisant regulates the release of other neurotransmitters involved in wake promotion, including dopamine, noradrenaline, and acetylcholine.[64562][64569]

        Revision Date: 12/05/2024, 02:07:00 AM

        References

        64562 - Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2024 Jun.64569 - Romigi A, Vitrani G, Lo Giudice T, et al. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther 2018;12:2665-2675.

        Pharmacokinetics

        Pitolisant is administered orally. The approximate apparent volume of distribution of pitolisant is 700 L (5 to 10 L/kg). Serum protein binding is 91% to 96%. The blood to plasma ratio of pitolisant is 0.55 to 0.89. Metabolism primarily occurs by CYP2D6 and to a lesser extent by CYP3A4. Metabolites are not pharmacologically active and they are further metabolized or conjugated with glycine or glucuronic acid. Approximately 90% of a single 17.8 mg dose is excreted in urine (less than 2% unchanged) and 2.3% is excreted in the feces. The median half-life of pitolisant is approximately 20 hours (7.5 to 24.2 hours) following administration of a single 35.6 mg dose.[64562]

         

        Affected cytochrome P450 (CYP450) isoenzymes and drug transporters: CYP2D6, CYP3A4

        Pitolisant is predominately metabolized by CYP2D6 and to a lesser extent by CYP3A4. Concomitant administration of pitolisant with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold, and dose reductions of pitolisant are needed. Strong CYP3A4 inducers decrease exposure of pitolisant by 50%; dose adjustments may be necessary in some patients, as long as the usual maximum dosage is not exceeded. Pitolisant is a borderline/weak inducer of CYP3A4. Therefore, reduced effectiveness of sensitive CYP3A4 substrates, such as hormonal contraceptives, may occur when used concomitantly with the drug.[64562]

        Route-Specific Pharmacokinetics

        Oral Route

        Oral absorption of pitolisant is approximately 90%. The Cmax and AUC of pitolisant are 73 ng/mL (range: 49.2 to 126 ng/mL) and 821 ng x hour/mL (range: 518 to 1,468 ng x hour/mL), respectively, following administration of 35.6 mg once daily. The Cmax and AUC increase proportionally with the dose. The Tmax of pitolisant is 3.5 hours (range 2 to 5 hours). Steady-state is reached by day 7 of treatment. No significant differences in the pharmacokinetics of pitolisant were observed following administration with a high-fat meal.[64562]

        Special Populations

        Hepatic Impairment

        The AUC of pitolisant was increased by an approximate factor of 3 among 6 subjects with moderate hepatic impairment (Child-Pugh B) compared to 12 healthy subjects following receipt of a single 17.8 mg dose. The Cmax increased by an approximate factor of 1.5 of among 6 subjects with moderate hepatic impairment; however, the increase was not statistically significant. Among 6 subjects with mild hepatic impairment (Child-Pugh A) there were no significant changes in Cmax or AUC compared to healthy subjects. The effects of severe hepatic impairment (Child-Pugh C) on the pharmacokinetics of pitolisant are unknown.[64562]

        Renal Impairment

        The Cmax of pitolisant increased by an approximate factor of 3 among 4 subjects with severe renal impairment (eGFR 15 to 29 mL/minute/1.73 m2) compared to 12 healthy subjects following receipt of a single 17.8 mg dose. AUC increased by an approximate factor 2 of among patients with severe renal impairment. In 4 subjects with moderate renal impairment (eGFR 30 to 59 mL/minute/1.73 m2), AUC and Cmax increased by approximate factors of 2 and 1.5, respectively; the increase in Cmax was not statistically significant. In 4 subjects with mild renal impairment (eGFR 60 mL/minute/1.73 m2 or more), AUC and Cmax increased by an approximate factor of 2; the increases in AUC were not statistically significant. The effects of end-stage renal disease (eGFR less than 15 mL/minute/1.73 m2) on the pharmacokinetics of pitolisant are unknown.[64562]

        Pediatrics

        Data from a single dose pharmacokinetic study of pediatric patients (7 to 17 years) with narcolepsy suggest that pediatric patients have an increased exposure to pitolisant compared to adults. The Cmax and AUC of pitolisant were 2.2- and 2-fold higher, respectively, in patients 12 to 17 years when compared with the adult population. In patients 7 to 11 years, the Cmax and AUC were 3.4- and 3.6-fold higher, respectively.[64562]

        Geriatric

        The pharmacokinetics of pitolisant were not affected by age.[64562]

        Gender Differences

        The pharmacokinetics of pitolisant were not affected by gender.[64562]

        Ethnic Differences

        The pharmacokinetics of pitolisant were not affected by race.[64562]

        Obesity

        The pharmacokinetics of pitolisant were not affected by body weight (48 to 103 kg).[64562]

        Other

        CYP2D6 Poor Metabolizers

        The Cmax and AUC of pitolisant increased approximately 2-fold among 3 CYP2D6 poor metabolizers compared to 5 CYP2D6 extensive (normal) metabolizers following receipt of pitolisant 17.8 mg for 7 days.[64562]

        Revision Date: 12/05/2024, 02:07:00 AM

        References

        64562 - Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2024 Jun.

        Pregnancy/Breast-feeding

        pregnancy

        There are no adequate data on the developmental risk associated with pitolisant use during human pregnancy. Available case reports from clinical trials and postmarketing reports with pitolisant use in pregnant women have not determined a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproductive studies, administration of pitolisant during organogenesis caused maternal and embryofetal toxicity in rats and rabbits at doses 13 or greater and 4 times or greater the maximum recommended human dose (MRHD) of 35.6 mg based on mg/square meter body surface area, respectively. The no observed adverse effect dose for maternal toxicity and embryofetal development were 2 and 4 times the MRHD based on body surface area, respectively. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to pitolisant during pregnancy. To enroll or obtain information, patients can call 1-800-833-7460. The effects of pitolisant during labor and obstetric delivery are unknown.[64562]

        breast-feeding

        Use pitolisant with caution during lactation; consider the developmental and health benefits of breast-feeding along with the mother's clinical need for pitolisant and any potential adverse effects on the breastfed infant from pitolisant or the underlying maternal condition. Pitolisant was found to pass into breast milk at low levels in an open-label study of 8 healthy lactating women who were 11 to 96 weeks postpartum. The concentration of pitolisant was evaluated in breast milk samples collected over 24 hours and serum samples were collected over 120 hours after a single dose of 35.6 mg of pitolisant was administered. Approximately 50% of the amount of pitolisant measured in breast milk occurred during the first 4 hours post dose. Based on the study, the mean infant dose was 0.009 mg/day, less than 1% of the maternal weight-adjusted dose. There are no data on the effects of pitolisant on the breastfed infant or the effect of pitolisant on milk production.[64562]

        Revision Date: 12/05/2024, 02:07:00 AM

        References

        64562 - Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2024 Jun.

        Interactions

        Level 1 (Severe)

        • Cisapride
        • Dronedarone
        • Ketoconazole
        • Levoketoconazole
        • Pimozide
        • Thioridazine

        Level 2 (Major)

        • Acetaminophen; Aspirin; Diphenhydramine
        • Acetaminophen; Caffeine; Pyrilamine
        • Acetaminophen; Chlorpheniramine
        • Acetaminophen; Chlorpheniramine; Dextromethorphan
        • Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine
        • Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine
        • Acetaminophen; Chlorpheniramine; Phenylephrine
        • Acetaminophen; Dextromethorphan; Doxylamine
        • Acetaminophen; Diphenhydramine
        • Acetaminophen; Pamabrom; Pyrilamine
        • Acrivastine; Pseudoephedrine
        • Adagrasib
        • Alfuzosin
        • Amiodarone
        • Amisulpride
        • Amitriptyline
        • Amobarbital
        • Amoxicillin; Clarithromycin; Omeprazole
        • Anagrelide
        • Apalutamide
        • Apomorphine
        • Aripiprazole
        • Arsenic Trioxide
        • Artemether; Lumefantrine
        • Asenapine
        • Aspirin, ASA; Butalbital; Caffeine
        • Atogepant
        • Atomoxetine
        • Azelastine
        • Azelastine; Fluticasone
        • Azithromycin
        • Barbiturates
        • Bedaquiline
        • Bismuth Subcitrate Potassium; Metronidazole; Tetracycline
        • Bismuth Subsalicylate; Metronidazole; Tetracycline
        • Brompheniramine
        • Brompheniramine; Dextromethorphan; Phenylephrine
        • Brompheniramine; Phenylephrine
        • Brompheniramine; Pseudoephedrine
        • Brompheniramine; Pseudoephedrine; Dextromethorphan
        • Buprenorphine
        • Buprenorphine; Naloxone
        • Bupropion
        • Bupropion; Naltrexone
        • Butalbital; Acetaminophen
        • Butalbital; Acetaminophen; Caffeine
        • Butalbital; Acetaminophen; Caffeine; Codeine
        • Butalbital; Aspirin; Caffeine; Codeine
        • Cabotegravir; Rilpivirine
        • Carbamazepine
        • Carbinoxamine
        • Cariprazine
        • Ceritinib
        • Chlophedianol; Dexbrompheniramine
        • Chlophedianol; Dexchlorpheniramine; Pseudoephedrine
        • Chlorcyclizine
        • Chlordiazepoxide; Amitriptyline
        • Chloroquine
        • Chlorpheniramine
        • Chlorpheniramine; Codeine
        • Chlorpheniramine; Dextromethorphan
        • Chlorpheniramine; Dextromethorphan; Phenylephrine
        • Chlorpheniramine; Dextromethorphan; Pseudoephedrine
        • Chlorpheniramine; Hydrocodone
        • Chlorpheniramine; Ibuprofen; Pseudoephedrine
        • Chlorpheniramine; Phenylephrine
        • Chlorpheniramine; Pseudoephedrine
        • Chlorpromazine
        • Ciprofloxacin
        • Citalopram
        • Clarithromycin
        • Clemastine
        • Clofazimine
        • Clomipramine
        • Clozapine
        • Codeine; Phenylephrine; Promethazine
        • Codeine; Promethazine
        • Crizotinib
        • Cyproheptadine
        • Dacomitinib
        • Dasatinib
        • Degarelix
        • Desflurane
        • Desipramine
        • Desogestrel; Ethinyl Estradiol
        • Deutetrabenazine
        • Dexbrompheniramine
        • Dexbrompheniramine; Dextromethorphan; Phenylephrine
        • Dexbrompheniramine; Pseudoephedrine
        • Dexchlorpheniramine
        • Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine
        • Dexmedetomidine
        • Dextromethorphan; Bupropion
        • Dextromethorphan; Diphenhydramine; Phenylephrine
        • Dextromethorphan; Quinidine
        • Dienogest; Estradiol valerate
        • Dimenhydrinate
        • Diphenhydramine
        • Diphenhydramine; Ibuprofen
        • Diphenhydramine; Naproxen
        • Diphenhydramine; Phenylephrine
        • Disopyramide
        • Dofetilide
        • Dolasetron
        • Dolutegravir; Rilpivirine
        • Donepezil
        • Donepezil; Memantine
        • Doxepin
        • Doxylamine
        • Doxylamine; Pyridoxine
        • Droperidol
        • Drospirenone
        • Drospirenone; Estetrol
        • Drospirenone; Estradiol
        • Drospirenone; Ethinyl Estradiol
        • Drospirenone; Ethinyl Estradiol; Levomefolate
        • Efavirenz
        • Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate
        • Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate
        • Elagolix; Estradiol; Norethindrone acetate
        • Eliglustat
        • Emtricitabine; Rilpivirine; Tenofovir alafenamide
        • Emtricitabine; Rilpivirine; Tenofovir Disoproxil Fumarate
        • Encorafenib
        • Entrectinib
        • Enzalutamide
        • Eribulin
        • Erythromycin
        • Escitalopram
        • Estradiol; Levonorgestrel
        • Estradiol; Norethindrone
        • Estradiol; Norgestimate
        • Ethinyl Estradiol; Norelgestromin
        • Ethinyl Estradiol; Norethindrone Acetate
        • Ethinyl Estradiol; Norgestrel
        • Ethynodiol Diacetate; Ethinyl Estradiol
        • Etonogestrel
        • Etonogestrel; Ethinyl Estradiol
        • Etrasimod
        • Fexinidazole
        • Fingolimod
        • Flecainide
        • Fluconazole
        • Fluoxetine
        • Fluvoxamine
        • Foscarnet
        • Fosphenytoin
        • Fostemsavir
        • Gemifloxacin
        • Gemtuzumab Ozogamicin
        • Gilteritinib
        • Givinostat
        • Glasdegib
        • Goserelin
        • Granisetron
        • Halogenated Anesthetics
        • Haloperidol
        • Histrelin
        • Hydroxychloroquine
        • Hydroxyzine
        • Ibutilide
        • Iloperidone
        • Imipramine
        • Inotuzumab Ozogamicin
        • Isoflurane
        • Isoniazid, INH; Pyrazinamide, PZA; Rifampin
        • Isoniazid, INH; Rifampin
        • Itraconazole
        • Ivosidenib
        • Lansoprazole; Amoxicillin; Clarithromycin
        • Lapatinib
        • Lefamulin
        • Lenvatinib
        • Leuprolide
        • Leuprolide; Norethindrone
        • Levofloxacin
        • Levonorgestrel
        • Levonorgestrel; Ethinyl Estradiol
        • Levonorgestrel; Ethinyl Estradiol; Ferrous Bisglycinate
        • Levonorgestrel; Ethinyl Estradiol; Ferrous Fumarate
        • Lithium
        • Lofexidine
        • Loperamide
        • Loperamide; Simethicone
        • Lopinavir; Ritonavir
        • Lumacaftor; Ivacaftor
        • Lumacaftor; Ivacaftor
        • Lumateperone
        • Macimorelin
        • Maprotiline
        • Mavorixafor
        • Meclizine
        • Methadone
        • Methohexital
        • Metronidazole
        • Midostaurin
        • Mifepristone
        • Mirtazapine
        • Mitotane
        • Mobocertinib
        • Moxifloxacin
        • Nilotinib
        • Non-oral combination contraceptives
        • Norethindrone
        • Norethindrone Acetate; Ethinyl Estradiol; Ferrous fumarate
        • Norethindrone; Ethinyl Estradiol
        • Norethindrone; Ethinyl Estradiol; Ferrous fumarate
        • Norgestimate; Ethinyl Estradiol
        • Norgestrel
        • Nortriptyline
        • Ofloxacin
        • Olanzapine
        • Olanzapine; Fluoxetine
        • Olanzapine; Samidorphan
        • Ondansetron
        • Oral Contraceptives
        • Osilodrostat
        • Osimertinib
        • Oxaliplatin
        • Ozanimod
        • Pacritinib
        • Paliperidone
        • Panobinostat
        • Paroxetine
        • Pasireotide
        • Pazopanib
        • Pentamidine
        • PENTobarbital
        • Perphenazine; Amitriptyline
        • Phenobarbital
        • Phenobarbital; Hyoscyamine; Atropine; Scopolamine
        • Phenytoin
        • Pimavanserin
        • Ponesimod
        • Posaconazole
        • Primaquine
        • Primidone
        • Procainamide
        • Promethazine
        • Promethazine; Dextromethorphan
        • Promethazine; Phenylephrine
        • Propafenone
        • Protriptyline
        • Quetiapine
        • Quinidine
        • Quinine
        • Quizartinib
        • Ranolazine
        • Relugolix
        • Relugolix; Estradiol; Norethindrone acetate
        • Revumenib
        • Ribociclib
        • Ribociclib; Letrozole
        • Rifampin
        • Rifapentine
        • Rilpivirine
        • Risperidone
        • Romidepsin
        • Saquinavir
        • Secobarbital
        • Segesterone Acetate; Ethinyl Estradiol
        • Selpercatinib
        • Sertraline
        • Sevoflurane
        • Siponimod
        • Sodium Stibogluconate
        • Solifenacin
        • Sorafenib
        • Sotalol
        • St. John's Wort, Hypericum perforatum
        • Sunitinib
        • Tacrolimus
        • Tamoxifen
        • Telavancin
        • Terbinafine
        • Tetrabenazine
        • Tipranavir
        • Tolterodine
        • Toremifene
        • Trazodone
        • Triclabendazole
        • Tricyclic antidepressants
        • Trimipramine
        • Triptorelin
        • Vandetanib
        • Vardenafil
        • Vemurafenib
        • Venlafaxine
        • Voclosporin
        • Vonoprazan; Amoxicillin; Clarithromycin
        • Voriconazole
        • Vorinostat
        • Ziprasidone

        Level 3 (Moderate)

        • Celecoxib; Tramadol
        • Nanoparticle Albumin-Bound Sirolimus
        • Nirmatrelvir; Ritonavir
        • Ritonavir
        • Sirolimus
        • Tramadol
        • Tramadol; Acetaminophen
        • Warfarin

        Level 4 (Minor)

        • Fluphenazine
        • Mefloquine
        • Perphenazine
        • Prochlorperazine
        • Trifluoperazine
        Acetaminophen; Aspirin; diphenhydrAMINE: (Major) Avoid coadministration of pitolisant with diphenhydramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like diphenhydramine, may reduce pitolisant efficacy. [64562] Acetaminophen; Caffeine; Pyrilamine: (Major) Avoid coadministration of pitolisant with pyrilamine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like pyrilamine, may reduce pitolisant efficacy. [64562] Acetaminophen; Chlorpheniramine: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Acetaminophen; Chlorpheniramine; Dextromethorphan: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Acetaminophen; Chlorpheniramine; Phenylephrine : (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Acetaminophen; Dextromethorphan; Doxylamine: (Major) Avoid coadministration of pitolisant with doxylamine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like doxylamine, may reduce pitolisant efficacy. [64562] Acetaminophen; diphenhydrAMINE: (Major) Avoid coadministration of pitolisant with diphenhydramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like diphenhydramine, may reduce pitolisant efficacy. [64562] Acetaminophen; Pamabrom; Pyrilamine: (Major) Avoid coadministration of pitolisant with pyrilamine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like pyrilamine, may reduce pitolisant efficacy. [64562] Acrivastine; Pseudoephedrine: (Major) Avoid coadministration of pitolisant with acrivastine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like acrivastine, may reduce pitolisant efficacy. [64562] Adagrasib: (Major) Concomitant use of adagrasib and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [64562] [68325] Alfuzosin: (Major) Avoid coadministration of pitolisant with alfuzosin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Alfuzosin may prolong the QT interval in a dose-dependent manner. [28261] [64562] Amiodarone: (Major) Concomitant use of amiodarone and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Due to the extremely long half-life of amiodarone, a drug interaction is possible for days to weeks after drug discontinuation. [28224] [28432] [28457] [64562] Amisulpride: (Major) Avoid coadministration of pitolisant with amisulpride as concurrent use may increase the risk of QT prolongation. If concomitant therapy is unavoidable, monitor ECGs. Amisulpride causes dose- and concentration- dependent QT prolongation. [64562] [65068] Amitriptyline: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] Amobarbital: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Amoxicillin; Clarithromycin; Omeprazole: (Major) Avoid coadministration of pitolisant with clarithromycin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Clarithromycin is associated with an established risk for QT prolongation and torsade de pointes (TdP). [28225] [28238] [64562] Anagrelide: (Major) Avoid coadministration of pitolisant with anagrelide as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Torsade de pointes (TdP) and ventricular tachycardia have been reported with anagrelide. In addition, dose-related increases in mean QTc and heart rate were observed in healthy subjects. [30163] [64562] Apalutamide: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with apalutamide is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and apalutamide is a strong CYP3A inducer. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [62874] [64562] Apomorphine: (Major) Avoid coadministration of pitolisant with apomorphine since concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Dose-related QTc prolongation is associated with therapeutic apomorphine exposure. [28661] [64562] ARIPiprazole: (Major) Concomitant use of pitolisant and aripiprazole increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [42845] [64562] Arsenic Trioxide: (Major) Avoid coadministration of pitolisant with arsenic trioxide as concurrent use may increase the risk of QT prolongation. If concomitant drug use is unavoidable, frequently monitor electrocardiograms. Pitolisant prolongs the QT interval. Torsade de pointes (TdP), QT interval prolongation, and complete atrioventricular block have been reported with arsenic trioxide use. [59438] [64562] Artemether; Lumefantrine: (Major) Avoid coadministration of pitolisant with artemether; lumefantrine as concurrent use may increase the risk of QT prolongation. Consider ECG monitoring if pitolisant must be used with or after artemether; lumefantrine treatment. Pitolisant prolongs the QT interval. Artemether; lumefantrine is associated with prolongation of the QT interval. [35401] [64562] Asenapine: (Major) Avoid coadministration of pitolisant with asenapine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Asenapine has been associated with QT prolongation. [36343] [64562] Aspirin, ASA; Butalbital; Caffeine: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Atogepant: (Major) Avoid use of atogepant and pitolisant when atogepant is used for chronic migraine. Use an atogepant dose of 30 or 60 mg PO once daily for episodic migraine if coadministered with pitolisant. Concurrent use may decrease atogepant exposure and reduce efficacy. Atogepant is a CYP3A substrate and pitolisant is a weak CYP3A inducer. Coadministration with a weak CYP3A inducer resulted in a 25% reduction in atogepant overall exposure and a 24% reduction in atogepant peak concentration. [64562] [67011] Atomoxetine: (Major) Concomitant use of pitolisant and atomoxetine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28405] [64562] Azelastine: (Major) Avoid coadministration of pitolisant with azelastine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like azelastine, may reduce pitolisant efficacy. [64562] Azelastine; Fluticasone: (Major) Avoid coadministration of pitolisant with azelastine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like azelastine, may reduce pitolisant efficacy. [64562] Azithromycin: (Major) Concomitant use of pitolisant and azithromycin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28855] [43974] [64562] [65157] [65170] Barbiturates: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Bedaquiline: (Major) Avoid coadministration of pitolisant with bedaquiline as concurrent use may increase the risk of QT prolongation. Monitor ECGs if coadministration is necessary. Discontinue bedaquiline if evidence of serious ventricular arrhythmia or QTcF interval greater than 500 ms. Both bedaquiline and pitolisant prolong the QT interval. [52746] [64562] Bismuth Subcitrate Potassium; metroNIDAZOLE; Tetracycline: (Major) Concomitant use of metronidazole and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [36894] [64562] Bismuth Subsalicylate; metroNIDAZOLE; Tetracycline: (Major) Concomitant use of metronidazole and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [36894] [64562] Brompheniramine: (Major) Avoid coadministration of pitolisant with brompheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like brompheniramine, may reduce pitolisant efficacy. [64562] Brompheniramine; Dextromethorphan; Phenylephrine: (Major) Avoid coadministration of pitolisant with brompheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like brompheniramine, may reduce pitolisant efficacy. [64562] Brompheniramine; Phenylephrine: (Major) Avoid coadministration of pitolisant with brompheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like brompheniramine, may reduce pitolisant efficacy. [64562] Brompheniramine; Pseudoephedrine: (Major) Avoid coadministration of pitolisant with brompheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like brompheniramine, may reduce pitolisant efficacy. [64562] Brompheniramine; Pseudoephedrine; Dextromethorphan: (Major) Avoid coadministration of pitolisant with brompheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like brompheniramine, may reduce pitolisant efficacy. [64562] Buprenorphine: (Major) Concomitant use of pitolisant and buprenophine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [41235] [60270] [64562] Buprenorphine; Naloxone: (Major) Concomitant use of pitolisant and buprenophine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [41235] [60270] [64562] buPROPion: (Major) A pitolisant dosage reduction may be required during concomitant bupropion use. For patients on a stable dose of pitolisant, reduce the pitolisant dosage by half. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Concomitant use may increase pitolisant exposure and the risk for pitolisant-related adverse effects. Pitolisant is a CYP2D6 substrate and bupropion is a strong CYP2D6 inhibitor. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. [41057] [64562] buPROPion; Naltrexone: (Major) A pitolisant dosage reduction may be required during concomitant bupropion use. For patients on a stable dose of pitolisant, reduce the pitolisant dosage by half. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Concomitant use may increase pitolisant exposure and the risk for pitolisant-related adverse effects. Pitolisant is a CYP2D6 substrate and bupropion is a strong CYP2D6 inhibitor. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. [41057] [64562] Butalbital; Acetaminophen: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Butalbital; Acetaminophen; Caffeine: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Butalbital; Acetaminophen; Caffeine; Codeine: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Butalbital; Aspirin; Caffeine; Codeine: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Cabotegravir; Rilpivirine: (Major) Avoid coadministration of pitolisant with rilpivirine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [44376] [64562] carBAMazepine: (Major) Concomitant use of pitolisant and carbamazepine may decrease the exposure of both drugs which may reduce their efficacy. For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with carbamazepine is necessary. Additionally, monitor carbamazepine concentrations closely during coadministration; carbamazepine dose adjustments may be needed. Pitolisant is a CYP3A substrate and weak CYP3A inducer and carbamazepine is a CYP3A substrate and strong CYP3A inducer. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [41237] [56579] [64562] Carbinoxamine: (Major) Avoid coadministration of pitolisant with carbinoxamine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like carbinoxamine, may reduce pitolisant efficacy. [64562] Cariprazine: (Major) Avoid concomitant use of cariprazine and pitolisant. Concurrent use may decrease cariprazine exposure which may reduce its efficacy. Cariprazine is a CYP3A substrate and pitolisant is a CYP3A inducer. [60164] [64562] Celecoxib; Tramadol: (Moderate) Monitor for reduced efficacy of tramadol and signs of opioid withdrawal if coadministration with pitolisant is necessary; consider increasing the dose of tramadol as needed. If pitolisant is discontinued, consider a dose reduction of tramadol and frequently monitor for seizures, serotonin syndrome, and signs of respiratory depression and sedation. Tramadol is a CYP3A substrate and pitolisant is a weak CYP3A inducer. Concomitant use with CYP3A inducers can decrease tramadol levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. [32475] [40255] [51440] [64562] Ceritinib: (Major) Avoid coadministration of pitolisant with ceritinib as concurrent use may increase the risk of QT prolongation. If concomitant use is unavoidable, periodically monitor ECGs and electrolytes; an interruption of ceritinib therapy, dose reduction, or discontinuation of therapy may be necessary if QT prolongation occurs. Ceritinib causes concentration-dependent QT prolongation. Pitolisant also prolongs the QT interval. [57094] [64562] Chlophedianol; Dexbrompheniramine: (Major) Avoid coadministration of pitolisant with dexbrompheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like dexbrompheniramine, may reduce pitolisant efficacy. [64562] Chlophedianol; Dexchlorpheniramine; Pseudoephedrine: (Major) Avoid coadministration of pitolisant with dexchlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like dexchlorpheniramine, may reduce pitolisant efficacy. [64562] Chlorcyclizine: (Major) Avoid coadministration of pitolisant with chlorcyclizine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorcyclizine, may reduce pitolisant efficacy. [64562] chlordiazePOXIDE; Amitriptyline: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] Chloroquine: (Major) Avoid coadministration of chloroquine with pitolisant due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Chloroquine is associated with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with higher chloroquine doses. Pitolisant also prolongs the QT interval. [28229] [28230] [28231] [29758] [64562] [65157] [65170] Chlorpheniramine: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Chlorpheniramine; Codeine: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Chlorpheniramine; Dextromethorphan: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Chlorpheniramine; Dextromethorphan; Phenylephrine: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Chlorpheniramine; Dextromethorphan; Pseudoephedrine: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Chlorpheniramine; HYDROcodone: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Chlorpheniramine; Ibuprofen; Pseudoephedrine: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Chlorpheniramine; Phenylephrine: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] Chlorpheniramine; Pseudoephedrine: (Major) Avoid coadministration of pitolisant with chlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like chlorpheniramine, may reduce pitolisant efficacy. [64562] chlorproMAZINE: (Major) Avoid coadministration of pitolisant with chlorpromazine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Chlorpromazine, a phenothiazine, is associated with an established risk of QT prolongation and torsade de pointes (TdP). [28415] [43065] [64562] Ciprofloxacin: (Major) Concomitant use of pitolisant and ciprofloxacin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28432] [28457] [29833] [33144] [33145] [33146] [43411] [48869] [48871] [64562] Cisapride: (Contraindicated) Coadministration of cisapride with pitolisant is contraindicated due to the potential for QT prolongation and torsade de pointes (TdP). QT prolongation and ventricular arrhythmias, including TdP and death, have been reported with cisapride. Pitolisant prolongs the QT interval. [28978] [47221] [64562] Citalopram: (Major) Concomitant use of pitolisant and citalopram increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28269] [64562] Clarithromycin: (Major) Avoid coadministration of pitolisant with clarithromycin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Clarithromycin is associated with an established risk for QT prolongation and torsade de pointes (TdP). [28225] [28238] [64562] Clemastine: (Major) Avoid coadministration of pitolisant with clemastine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like clemastine, may reduce pitolisant efficacy. [64562] Clofazimine: (Major) Concomitant use of clofazimine and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [63936] [64562] clomiPRAMINE: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] cloZAPine: (Major) Avoid coadministration of pitolisant with clozapine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Treatment with clozapine has been associated with QT prolongation, torsade de pointes (TdP), cardiac arrest, and sudden death. [28262] [64562] Codeine; Phenylephrine; Promethazine: (Major) Avoid coadministration of pitolisant with promethazine as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like promethazine, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. Promethazine, a phenothiazine, is associated with a possible risk for QT prolongation. [28225] [55578] [64562] Codeine; Promethazine: (Major) Avoid coadministration of pitolisant with promethazine as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like promethazine, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. Promethazine, a phenothiazine, is associated with a possible risk for QT prolongation. [28225] [55578] [64562] Crizotinib: (Major) Avoid coadministration of crizotinib with pitolisant due to the risk of QT prolongation. If concomitant use is unavoidable, monitor ECGs for QT prolongation and monitor electrolytes. An interruption of therapy, dose reduction, or discontinuation of therapy may be necessary for crizotinib if QT prolongation occurs. Crizotinib can cause concentration-dependent QT prolongation. Pitolisant also prolongs the QT interval. [45458] [64562] Cyproheptadine: (Major) Avoid coadministration of pitolisant with cyproheptadine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like cyproheptadine, may reduce pitolisant efficacy. [64562] Dacomitinib: (Major) A pitolisant dosage reduction may be required during concomitant dacomitinib use. For patients on a stable dose of pitolisant, reduce the pitolisant dosage by half. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Concomitant use may increase pitolisant exposure and the risk for pitolisant-related adverse effects. Pitolisant is a CYP2D6 substrate and dacomitinib is a strong CYP2D6 inhibitor. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. [63584] [64562] Dasatinib: (Major) Avoid coadministration of pitolisant with dasatinib as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. In vitro studies have shown that dasatinib has the potential to prolong the QT interval. [32387] [64562] Degarelix: (Major) Avoid coadministration of pitolisant with degarelix as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Androgen deprivation therapy (i.e., degarelix) may prolong the QT/QTc interval. [46869] [64562] Desflurane: (Major) Avoid coadministration of pitolisant with halogenated anesthetics as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Halogenated anesthetics can also prolong the QT interval. [28457] [28458] [28754] [28755] [28756] [64562] Desipramine: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] Desogestrel; Ethinyl Estradiol: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Deutetrabenazine: (Major) Avoid coadministration of pitolisant with deutetrabenazine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Deutetrabenazine may prolong the QT interval, but the degree of QT prolongation is not clinically significant when deutetrabenazine is administered within the recommended dosage range. [61845] [64562] Dexbrompheniramine: (Major) Avoid coadministration of pitolisant with dexbrompheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like dexbrompheniramine, may reduce pitolisant efficacy. [64562] Dexbrompheniramine; Dextromethorphan; Phenylephrine: (Major) Avoid coadministration of pitolisant with dexbrompheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like dexbrompheniramine, may reduce pitolisant efficacy. [64562] Dexbrompheniramine; Pseudoephedrine: (Major) Avoid coadministration of pitolisant with dexbrompheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like dexbrompheniramine, may reduce pitolisant efficacy. [64562] Dexchlorpheniramine: (Major) Avoid coadministration of pitolisant with dexchlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like dexchlorpheniramine, may reduce pitolisant efficacy. [64562] Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine: (Major) Avoid coadministration of pitolisant with dexchlorpheniramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like dexchlorpheniramine, may reduce pitolisant efficacy. [64562] dexmedeTOMIDine: (Major) Concomitant use of dexmedetomidine and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [64562] [67509] Dextromethorphan; buPROPion: (Major) A pitolisant dosage reduction may be required during concomitant bupropion use. For patients on a stable dose of pitolisant, reduce the pitolisant dosage by half. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Concomitant use may increase pitolisant exposure and the risk for pitolisant-related adverse effects. Pitolisant is a CYP2D6 substrate and bupropion is a strong CYP2D6 inhibitor. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. [41057] [64562] Dextromethorphan; diphenhydrAMINE; Phenylephrine: (Major) Avoid coadministration of pitolisant with diphenhydramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like diphenhydramine, may reduce pitolisant efficacy. [64562] Dextromethorphan; quiNIDine: (Major) Concomitant use of pitolisant and quinidine increases the risk of QT/QTc prolongation and torsade de pointes (TdP) and may increase pitolisant exposure and the risk for other adverse effects. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. If concomitant use is necessary, reduce the pitolisant dosage by half for patients on a stable dose of pitolisant. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Additionally, consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring. Pitolisant is a CYP2D6 substrate, quinidine is a strong CYP2D6 inhibitor, and both medications have been associated with QT/QTc prolongation. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. [42280] [47357] [64562] Dienogest; Estradiol valerate: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] dimenhyDRINATE: (Major) Avoid coadministration of pitolisant with dimenhydrinate as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like dimenhydrinate, may reduce pitolisant efficacy. [64562] diphenhydrAMINE: (Major) Avoid coadministration of pitolisant with diphenhydramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like diphenhydramine, may reduce pitolisant efficacy. [64562] diphenhydrAMINE; Ibuprofen: (Major) Avoid coadministration of pitolisant with diphenhydramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like diphenhydramine, may reduce pitolisant efficacy. [64562] diphenhydrAMINE; Naproxen: (Major) Avoid coadministration of pitolisant with diphenhydramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like diphenhydramine, may reduce pitolisant efficacy. [64562] diphenhydrAMINE; Phenylephrine: (Major) Avoid coadministration of pitolisant with diphenhydramine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like diphenhydramine, may reduce pitolisant efficacy. [64562] Disopyramide: (Major) Avoid coadministration of pitolisant with disopyramide as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Disopyramide administration is associated with QT prolongation and torsade de pointes (TdP). [28228] [64562] Dofetilide: (Major) Coadministration of dofetilide and pitolisant is not recommended as concurrent use may increase the risk of QT prolongation. Dofetilide, a Class III antiarrhythmic agent, is associated with a well-established risk of QT prolongation and TdP. Pitolisant also prolongs the QT interval. [28221] [28432] [28457] [64562] Dolasetron: (Major) Avoid coadministration of pitolisant with dolasetron as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Dolasetron has been associated with a dose-dependent prolongation in the QT, PR, and QRS intervals on an electrocardiogram. [28308] [50275] [64562] Dolutegravir; Rilpivirine: (Major) Avoid coadministration of pitolisant with rilpivirine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [44376] [64562] Donepezil: (Major) Avoid coadministration of pitolisant with donepezil as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Case reports indicate that QT prolongation and torsade de pointes (TdP) can occur during donepezil therapy. [59321] [59322] [64562] Donepezil; Memantine: (Major) Avoid coadministration of pitolisant with donepezil as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Case reports indicate that QT prolongation and torsade de pointes (TdP) can occur during donepezil therapy. [59321] [59322] [64562] Doxepin: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] Doxylamine: (Major) Avoid coadministration of pitolisant with doxylamine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like doxylamine, may reduce pitolisant efficacy. [64562] Doxylamine; Pyridoxine: (Major) Avoid coadministration of pitolisant with doxylamine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like doxylamine, may reduce pitolisant efficacy. [64562] Dronedarone: (Contraindicated) Coadministration of dronedarone with pitolisant is contraindicated due to the potential for QT prolongation and torsade de pointes (TdP). Pitolisant prolongs the QT interval. Dronedarone administration is associated with a dose-related increase in the QTc interval. The increase in QTc is approximately 10 milliseconds at doses of 400 mg twice daily (the FDA-approved dose) and up to 25 milliseconds at doses of 1,600 mg twice daily. Although there are no studies examining the effects of dronedarone in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation. [36101] [64562] droPERidol: (Major) Avoid coadministration of pitolisant with droperidol as concurrent use may increase the risk of QT prolongation. If coadministration cannot be avoided, use extreme caution; initiate droperidol at a low dose and increase the dose as needed to achieve the desired effect. Droperidol administration is associated with an established risk for QT prolongation and torsade de pointes (TdP). Some cases have occurred in patients with no known risk factors for QT prolongation and some cases have been. Pitolisant also prolongs the QT interval. [28235] [28236] [28737] [51289] [64562] Drospirenone: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Drospirenone; Estetrol: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Drospirenone; Estradiol: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Drospirenone; Ethinyl Estradiol: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Drospirenone; Ethinyl Estradiol; Levomefolate: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Efavirenz: (Major) Avoid coadministration of pitolisant with efavirenz as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. QTc prolongation has been observed with the use of efavirenz. [28442] [64562] Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of pitolisant with efavirenz as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. QTc prolongation has been observed with the use of efavirenz. [28442] [64562] Efavirenz; lamiVUDine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of pitolisant with efavirenz as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. QTc prolongation has been observed with the use of efavirenz. [28442] [64562] Elagolix; Estradiol; Norethindrone acetate: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Eliglustat: (Major) Avoid coadministration of pitolisant with eliglustat as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Eliglustat is predicted to cause PR, QRS, and/or QT prolongation at significantly elevated plasma concentrations. [57803] [64562] Emtricitabine; Rilpivirine; Tenofovir alafenamide: (Major) Avoid coadministration of pitolisant with rilpivirine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [44376] [64562] Emtricitabine; Rilpivirine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of pitolisant with rilpivirine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [44376] [64562] Encorafenib: (Major) Concomitant use of encorafenib and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP) and may decrease pitolisant exposure which may reduce its efficacy. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. If concomitant use is necessary, for patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days. Additionally, consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring. Pitolisant is a CYP3A substrate, encorafenib is a strong CYP3A inducer, and both medications have been associated with QT/QTc prolongation. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [63317] [64562] Entrectinib: (Major) Avoid coadministration of pitolisant with entrectinib as concurrent use may increase the risk of QT prolongation. Entrectinib has been associated with QT prolongation. Pitolisant also prolongs the QT interval. [64562] [64567] Enzalutamide: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with enzalutamide is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and enzalutamide is a strong CYP3A inducer. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [51727] [64562] eriBULin: (Major) Avoid coadministration of pitolisant with eribulin as concurrent use may increase the risk of QT prolongation. If coadministration is necessary, monitor ECG. Eribulin has been associated with QT prolongation. Pitolisant also prolongs the QT interval. [42449] [64562] Erythromycin: (Major) Concomitant use of pitolisant and erythromycin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [43258] [64562] Escitalopram: (Major) Concomitant use of pitolisant and escitalopram increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28270] [64562] Estradiol; Levonorgestrel: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Estradiol; Norethindrone: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Estradiol; Norgestimate: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Ethinyl Estradiol; Norelgestromin: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Ethinyl Estradiol; Norethindrone Acetate: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Ethinyl Estradiol; Norgestrel: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Ethynodiol Diacetate; Ethinyl Estradiol: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Etonogestrel: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Etonogestrel; Ethinyl Estradiol: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Etrasimod: (Major) Concomitant use of etrasimod and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Etrasimod has a limited effect on the QT/QTc interval at therapeutic doses but may cause bradycardia and atrioventricular conduction delays which may increase the risk for TdP in patients with a prolonged QT/QTc interval. [64562] [69114] Fexinidazole: (Major) Concomitant use of fexinidazole and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [64562] [66812] Fingolimod: (Major) Avoid coadministration of pitolisant with fingolimod as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Fingolimod initiation results in decreased heart rate and may prolong the QT interval. Fingolimod has not been studied in patients treated with drugs that prolong the QT interval, but drugs that prolong the QT interval have been associated with cases of TdP in patients with bradycardia. [41823] [64562] Flecainide: (Major) Concomitant use of pitolisant and flecainide increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [23774] [28752] [64562] Fluconazole: (Major) Concomitant use of pitolisant and fluconazole increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28674] [64562] FLUoxetine: (Major) Concomitant use of pitolisant and fluoxetine increases the risk of QT/QTc prolongation and torsade de pointes (TdP) and may increase pitolisant exposure and the risk for other adverse effects. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. If concomitant use is necessary, reduce the pitolisant dosage by half for patients on a stable dose of pitolisant. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Additionally, consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring. Pitolisant is a CYP2D6 substrate, fluoxetine is a strong CYP2D6 inhibitor, and both medications have been associated with QT/QTc prolongation. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. [32061] [32062] [44058] [53347] [64562] fluPHENAZine: (Minor) Fluphenazine is associated with a possible risk for QT prolongation. Theoretically, fluphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation, such as pitolisant. [28415] [64562] fluvoxaMINE: (Major) Avoid coadministration of pitolisant with fluvoxamine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. QT prolongation and torsade de pointes (TdP) has been reported during fluvoxamine postmarketing use. [50507] [64562] Foscarnet: (Major) Avoid coadministration of pitolisant with foscarnet as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Both QT prolongation and torsade de pointes (TdP) have been reported during postmarketing use of foscarnet. [28377] [64562] Fosphenytoin: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with fosphenytoin is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and fosphenytoin is a strong CYP3A inducer. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [56579] [64562] Fostemsavir: (Major) Avoid coadministration of pitolisant with fostemsavir as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Supratherapeutic doses of fostemsavir (2,400 mg twice daily, four times the recommended daily dose) have been shown to cause QT prolongation. Fostemsavir causes dose-dependent QT prolongation. [64562] [65666] Gemifloxacin: (Major) Avoid coadministration of pitolisant with gemifloxacin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Gemifloxacin may prolong the QT interval in some patients. The maximal change in the QTc interval occurs approximately 5 to 10 hours following oral administration of gemifloxacin. The likelihood of QTc prolongation may increase with increasing dose of the drug; therefore, the recommended dose should not be exceeded especially in patients with renal or hepatic impairment where the Cmax and AUC are slightly higher. [28424] [28432] [28457] [29833] [33144] [33145] [33146] [48869] [48871] [64562] Gemtuzumab Ozogamicin: (Major) Avoid coadministration of pitolisant with gemtuzumab ozogamicin as concurrent use may increase the risk of QT prolongation. If these agents are used together, obtain an ECG and serum electrolytes prior to the start of gemtuzumab and as needed during treatment. Pitolisant prolongs the QT interval. Although QT interval prolongation has not been reported with gemtuzumab, it has been reported with other drugs that contain calicheamicin. [62292] [64562] Gilteritinib: (Major) Avoid coadministration of pitolisant with gilteritinib as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Gilteritinib has also been associated with QT prolongation. [63787] [64562] Givinostat: (Major) Concomitant use of givinostat and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. The degree of QT prolongation associated with givinostat is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 5 times the maximum recommended dose. [64562] [70477] Glasdegib: (Major) Avoid coadministration of glasdegib with pitolisant due to the potential for additive QT prolongation. If coadministration cannot be avoided, monitor patients for increased risk of QT prolongation with increased frequency of ECG monitoring. Glasdegib therapy may result in QT prolongation and ventricular arrhythmias including ventricular fibrillation and ventricular tachycardia. Pitolisant also prolongs the QT interval. [63777] [64562] Goserelin: (Major) Avoid coadministration of pitolisant with goserelin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Androgen deprivation therapy (i.e., goserelin) may also prolong the QT/QTc interval. [28592] [64562] Granisetron: (Major) Avoid coadministration of pitolisant with granisetron as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Granisetron has been associated with QT prolongation. [31723] [64562] Halogenated Anesthetics: (Major) Avoid coadministration of pitolisant with halogenated anesthetics as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Halogenated anesthetics can also prolong the QT interval. [28457] [28458] [28754] [28755] [28756] [64562] Haloperidol: (Major) Avoid coadministration of pitolisant with haloperidol as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. QT prolongation and torsade de pointes (TdP) have been observed during haloperidol treatment. Excessive doses (particularly in the overdose setting) or IV administration of haloperidol may be associated with a higher risk of QT prolongation. [23500] [23779] [28307] [28415] [64562] Histrelin: (Major) Avoid coadministration of pitolisant with histrelin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Androgen deprivation therapy (i.e., histrelin) may prolong the QT/QTc interval. [30369] [64562] Hydroxychloroquine: (Major) Concomitant use of pitolisant and hydroxychloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [41806] [64562] [65157] [65170] hydrOXYzine: (Major) Avoid coadministration of pitolisant with hydroxyzine as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like hydroxyzine, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. Postmarketing data indicate that hydroxyzine causes QT prolongation and torsade de pointes (TdP). [47129] [64562] Ibutilide: (Major) Avoid coadministration of pitolisant with ibutilide as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Ibutilide administration can cause QT prolongation and torsade de pointes (TdP); proarrhythmic events should be anticipated. The potential for proarrhythmic events with ibutilide increases with the coadministration of other drugs that prolong the QT interval. [41830] [64562] Iloperidone: (Major) Avoid coadministration of pitolisant with iloperidone as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Iloperidone has also been associated with QT prolongation. [36146] [64562] Imipramine: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] Inotuzumab Ozogamicin: (Major) Avoid coadministration of inotuzumab with pitolisant due to the potential for additive QT prolongation and torsade de pointes. If coadministration cannot be avoided, monitor ECG before and during treatment. Inotuzumab has been associated with QT interval prolongation. Pitolisant also prolongs the QT interval. [62245] [64562] Isoflurane: (Major) Avoid coadministration of pitolisant with halogenated anesthetics as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Halogenated anesthetics can also prolong the QT interval. [28457] [28458] [28754] [28755] [28756] [64562] Isoniazid, INH; Pyrazinamide, PZA; rifAMPin: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with rifampin is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and rifampin is a strong CYP3A inducer. Concomitant use reduced pitolisant overall exposure by 50%. [56579] [64562] Isoniazid, INH; rifAMPin: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with rifampin is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and rifampin is a strong CYP3A inducer. Concomitant use reduced pitolisant overall exposure by 50%. [56579] [64562] Itraconazole: (Major) Avoid coadministration of pitolisant with itraconazole as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Itraconazole has been associated with prolongation of the QT interval. [40233] [57441] [64562] Ivosidenib: (Major) Avoid coadministration of ivosidenib with pitolisant due to an increased risk of QT prolongation. If concomitant use is unavoidable, monitor ECGs for QTc prolongation and monitor electrolytes; correct any electrolyte abnormalities as clinically appropriate. An interruption of therapy and dose reduction of ivosidenib may be necessary if QT prolongation occurs. Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with ivosidenib. Pitolisant prolongs the QT interval. [63368] [64562] Ketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and pitolisant due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. [27982] [64562] [67231] Lansoprazole; Amoxicillin; Clarithromycin: (Major) Avoid coadministration of pitolisant with clarithromycin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Clarithromycin is associated with an established risk for QT prolongation and torsade de pointes (TdP). [28225] [28238] [64562] Lapatinib: (Major) Avoid coadministration of pitolisant with lapatinib as concurrent use may increase the risk of QT prolongation. If concomitant use is necessary, monitor for evidence of QT prolongation. Pitolisant prolongs the QT interval. Lapatinib has been associated with concentration-dependent QT prolongation; ventricular arrhythmias and torsade de pointes (TdP) have been reported in postmarketing experience with lapatinib. [33192] [64562] Lefamulin: (Major) Avoid coadministration of lefamulin with pitolisant as concurrent use may increase the risk of QT prolongation. If coadministration cannot be avoided, monitor ECG during treatment. Lefamulin has a concentration dependent QTc prolongation effect. The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between lefamulin and other drugs that effect cardiac conduction is unknown. Pitolisant prolongs the QT interval. [64562] [64576] Lenvatinib: (Major) Avoid coadministration of pitolisant with lenvatinib as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Prolongation of the QT interval has also been reported with lenvatinib therapy. [58782] [64562] Leuprolide: (Major) Avoid coadministration of pitolisant with leuprolide as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Androgen deprivation therapy (i.e., leuprolide) may prolong the QT/QTc interval. [64562] Leuprolide; Norethindrone: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] (Major) Avoid coadministration of pitolisant with leuprolide as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Androgen deprivation therapy (i.e., leuprolide) may prolong the QT/QTc interval. [64562] levoFLOXacin: (Major) Concomitant use of pitolisant and levofloxacin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28421] [28432] [28457] [29833] [33144] [33145] [33146] [48869] [48871] [64562] Levoketoconazole: (Contraindicated) Avoid concomitant use of ketoconazole and pitolisant due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. [27982] [64562] [67231] Levonorgestrel: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Levonorgestrel; Ethinyl Estradiol: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Levonorgestrel; Ethinyl Estradiol; Ferrous Bisglycinate: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Levonorgestrel; Ethinyl Estradiol; Ferrous Fumarate: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Lithium: (Major) Concomitant use of pitolisant and lithium increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [59809] [59810] [59811] [64562] Lofexidine: (Major) Avoid coadministration of pitolisant with lofexidine as concurrent use may increase the risk of QT prolongation. If coadministration cannot be avoided, ECG monitoring is recommended during treatment. Both pitolisant and lofexidine prolong the QT interval. [63161] [64562] Loperamide: (Major) Avoid coadministration of pitolisant with loperamide as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, torsade de pointes (TdP), and cardiac arrest. [30106] [60864] [64562] Loperamide; Simethicone: (Major) Avoid coadministration of pitolisant with loperamide as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, torsade de pointes (TdP), and cardiac arrest. [30106] [60864] [64562] Lopinavir; Ritonavir: (Major) Avoid coadministration of lopinavir with pitolisant due to the potential for additive QT prolongation. If use together is necessary, obtain a baseline ECG to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. Both drugs have been associated with QT prolongation. [28341] [64562] [65157] [65170] (Moderate) Monitor for decreased efficacy of ritonavir if coadministered with pitolisant. Concurrent use may decrease the plasma concentrations of ritonavir leading to a reduction of antiretroviral efficacy and the potential development of viral resistance. Ritonavir is a CYP3A substrate and pitolisant is a weak CYP3A inducer. [64562] [67203] Lumacaftor; Ivacaftor: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with lumacaftor; ivacaftor is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and lumacaftor; ivacaftor is a strong CYP3A inducer. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [59891] [64562] Lumacaftor; Ivacaftor: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with lumacaftor; ivacaftor is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and lumacaftor; ivacaftor is a strong CYP3A inducer. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [59891] [64562] Lumateperone: (Major) Avoid coadministration of lumateperone and pitolisant as concurrent use may decrease lumateperone exposure which may reduce efficacy. Lumateperone is a CYP3A substrate; pitolisant is a weak CYP3A inducer. [64562] [64885] Macimorelin: (Major) Avoid concurrent administration of macimorelin with drugs that prolong the QT interval, such as pitolisant. Use of these drugs together may increase the risk of developing torsade de pointes-type ventricular tachycardia. Sufficient washout time of drugs that are known to prolong the QT interval prior to administration of macimorelin is recommended. Treatment with macimorelin has been associated with an increase in the corrected QT (QTc) interval. [62723] [64562] Maprotiline: (Major) Avoid coadministration of pitolisant with maprotiline as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Maprotiline has been reported to prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). Cases of long QT syndrome and torsade de pointes (TdP) tachycardia have been described with maprotiline use, but rarely occur when the drug is used alone in normal prescribed doses and in the absence of other known risk factors for QT prolongation. Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. [28225] [28759] [64562] Mavorixafor: (Major) Concomitant use of pitolisant and mavorixafor increases the risk of QT/QTc prolongation and torsade de pointes (TdP) and may increase pitolisant exposure and the risk for other adverse effects. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. If concomitant use is necessary, reduce the pitolisant dosage by half for patients on a stable dose of pitolisant. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Additionally, consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring. Pitolisant is a CYP2D6 substrate, mavorixafor is a strong CYP2D6 inhibitor, and both medications have been associated with QT/QTc prolongation. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. The degree of QT prolongation associated with mavorixafor is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 2 times the maximum recommended dose. [64562] [70577] Meclizine: (Major) Avoid coadministration of pitolisant with meclizine as the effect of pitolisant may be decreased. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like meclizine, may reduce pitolisant efficacy. [64562] Mefloquine: (Minor) Coadministration of pitolisant and mefloquine may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. There is evidence that the use of halofantrine after mefloquine causes a significant lengthening of the QTc interval; however, mefloquine alone has not been reported to cause QT prolongation. [28301] [64562] Methadone: (Major) Avoid coadministration of pitolisant with methadone as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Methadone is considered to be associated with an increased risk for QT prolongation and torsade de pointes (TdP), especially at higher doses (more than 200 mg/day but averaging approximately 400 mg/day in adult patients). Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. [28319] [28320] [28321] [28322] [33136] [64562] Methohexital: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] metroNIDAZOLE: (Major) Concomitant use of metronidazole and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [36894] [64562] Midostaurin: (Major) Avoid coadministration of pitolisant with midostaurin as concurrent use may increase the risk of QT prolongation. If coadministration is necessary, consider interval assessments of QT by EKG. Pitolisant prolongs the QT interval. QT prolongation was reported in patients who received midostaurin in clinical trials. [61906] [64562] miFEPRIStone: (Major) Concomitant use of pitolisant and mifepristone increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [48697] [64562] Mirtazapine: (Major) Avoid coadministration of pitolisant with mirtazapine as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like mirtazapine, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. Mirtazapine has been associated with dose-dependent prolongation of the QT interval. Torsade de pointes (TdP) has been reported postmarketing, primarily in overdose or in patients with other risk factors for QT prolongation. [40942] [64562] Mitotane: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with mitotane is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and mitotane is a strong CYP3A inducer. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [41934] [64562] Mobocertinib: (Major) Concomitant use of mobocertinib and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [64562] [66990] Moxifloxacin: (Major) Avoid coadministration of moxifloxacin with pitolisant as concurrent use may increase the risk of QT prolongation and torsade de pointes (TdP). Quinolones have been associated with a risk of QT prolongation. Although extremely rare, TdP has been reported during postmarketing surveillance of moxifloxacin. These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory. Pitolisant prolongs the QT interval. [28423] [28432] [28457] [29833] [33144] [33145] [33146] [48869] [48871] [64562] Nanoparticle Albumin-Bound Sirolimus: (Moderate) Monitor for reduced sirolimus efficacy if sirolimus is coadministered with pitolisant. Concomitant use may decrease sirolimus exposure. Sirolimus is a CYP3A substrate and pitolisant is a weak CYP3A inducer. [64562] [67136] Nilotinib: (Major) Avoid coadministration of pitolisant with nilotinib as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Sudden death and QT interval prolongation have occurred in patients who received nilotinib therapy. [58766] [64562] Nirmatrelvir; Ritonavir: (Moderate) Monitor for a diminished response to nirmatrelvir if concomitant use of pitolisant is necessary. Concomitant use of nirmatrelvir and pitolisant may reduce the therapeutic effect of nirmatrelvir. Nirmatrelvir is a CYP3A substrate and pitolisant is a weak CYP3A inducer. [64562] [67203] (Moderate) Monitor for decreased efficacy of ritonavir if coadministered with pitolisant. Concurrent use may decrease the plasma concentrations of ritonavir leading to a reduction of antiretroviral efficacy and the potential development of viral resistance. Ritonavir is a CYP3A substrate and pitolisant is a weak CYP3A inducer. [64562] [67203] Non-oral combination contraceptives: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Norethindrone Acetate; Ethinyl Estradiol; Ferrous fumarate: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Norethindrone: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Norethindrone; Ethinyl Estradiol: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Norethindrone; Ethinyl Estradiol; Ferrous fumarate: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Norgestimate; Ethinyl Estradiol: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Norgestrel: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Nortriptyline: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] Ofloxacin: (Major) Concomitant use of pitolisant and ofloxacin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28432] [28457] [29833] [30738] [33144] [33145] [33146] [48869] [48871] [64562] OLANZapine: (Major) Avoid coadministration of pitolisant with olanzapine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. [28785] [32732] [32734] [32745] [32746] [64562] OLANZapine; FLUoxetine: (Major) Avoid coadministration of pitolisant with olanzapine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. [28785] [32732] [32734] [32745] [32746] [64562] (Major) Concomitant use of pitolisant and fluoxetine increases the risk of QT/QTc prolongation and torsade de pointes (TdP) and may increase pitolisant exposure and the risk for other adverse effects. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. If concomitant use is necessary, reduce the pitolisant dosage by half for patients on a stable dose of pitolisant. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Additionally, consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring. Pitolisant is a CYP2D6 substrate, fluoxetine is a strong CYP2D6 inhibitor, and both medications have been associated with QT/QTc prolongation. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. [32061] [32062] [44058] [53347] [64562] OLANZapine; Samidorphan: (Major) Avoid coadministration of pitolisant with olanzapine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval. [28785] [32732] [32734] [32745] [32746] [64562] Ondansetron: (Major) Concomitant use of pitolisant and ondansetron increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Do not exceed 16 mg of IV ondansetron in a single dose; the degree of QT prolongation associated with ondansetron significantly increases above this dose. [31266] [64562] Oral Contraceptives: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Osilodrostat: (Major) Avoid coadministration of pitolisant with osilodrostat as concurrent use may increase the risk of QT prolongation. If concomitant use is necessary, monitor ECGs. Pitolisant prolongs the QT interval. Osilodrostat is associated with dose-dependent QT prolongation. [64562] [65098] Osimertinib: (Major) Avoid coadministration of pitolisant with osimertinib due to the risk of QT prolongation and torsade de pointes (TdP). If concomitant use is unavoidable, periodically monitor ECGs for QT prolongation and monitor electrolytes; an interruption of osimertinib therapy with dose reduction or discontinuation may be necessary if QT prolongation occurs. Concentration-dependent QTc prolongation occurred during clinical trials of osimertinib. Pitolisant prolongs the QT interval. [60297] [64562] Oxaliplatin: (Major) Avoid coadministration of pitolisant with oxaliplatin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. QT prolongation and ventricular arrhythmias including fatal torsade de pointes have also been reported with oxaliplatin use in postmarketing experience. [41958] [64562] Ozanimod: (Major) In general, do not initiate ozanimod in patients taking pitolisant due to the risk of additive bradycardia, QT prolongation, and torsade de pointes (TdP). If treatment initiation is considered, seek advice from a cardiologist. Ozanimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays. Ozanimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia. Pitolisant prolongs the QT interval. [64562] [65169] Pacritinib: (Major) Concomitant use of pacritinib and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [64562] [67427] Paliperidone: (Major) Avoid coadministration of paliperidone with pitolisant due to the potential for additive QT prolongation and risk of torsade de pointes (TdP). Paliperidone has been associated with QT prolongation; torsade de pointes and ventricular fibrillation have been reported in the setting of overdose. Pitolisant prolongs the QT interval. [40936] [64562] Panobinostat: (Major) Avoid coadministration of pitolisant with panobinostat as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. QT prolongation has been reported with panobinostat. [58821] [64562] PARoxetine: (Major) A pitolisant dosage reduction may be required during concomitant paroxetine use. For patients on a stable dose of pitolisant, reduce the pitolisant dosage by half. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Concomitant use may increase pitolisant exposure and the risk for pitolisant-related adverse effects. Pitolisant is a CYP2D6 substrate and paroxetine is a strong CYP2D6 inhibitor. Concomitant use increased pitolisant overall exposure by 2.2-fold. [28260] [64562] Pasireotide: (Major) Avoid coadministration of pitolisant with pasireotide as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. QT prolongation has occurred with pasireotide at therapeutic and supra-therapeutic doses. [52611] [64562] PAZOPanib: (Major) Avoid coadministration of pitolisant with pazopanib as concurrent use may increase the risk of QT prolongation. If coadministration is necessary, closely monitor the patient for QT interval prolongation. Pitolisant prolongs the QT interval. Pazopanib has also been reported to prolong the QT interval. [37098] [64562] Pentamidine: (Major) Avoid coadministration of pitolisant with pentamidine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Systemic pentamidine has been associated with QT prolongation. [23620] [23778] [28419] [28879] [64562] PENTobarbital: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Perphenazine: (Minor) Perphenazine is associated with a possible risk for QT prolongation. Theoretically, perphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation, such as pitolisant. [28415] [64562] Perphenazine; Amitriptyline: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] (Minor) Perphenazine is associated with a possible risk for QT prolongation. Theoretically, perphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation, such as pitolisant. [28415] [64562] PHENobarbital: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] PHENobarbital; Hyoscyamine; Atropine; Scopolamine: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Phenytoin: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with phenytoin is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and phenytoin is a strong CYP3A inducer. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [56579] [64562] Pimavanserin: (Major) Avoid coadministration of pimavanserin with pitolisant due to additive QT effects and increased risk of cardiac arrhythmia. Both pimavanserin and pitolisant prolong the QT interval. [60748] [64562] Pimozide: (Contraindicated) Coadministration of pimozide with pitolisant is contraindicated due to the potential for QT prolongation and torsade de pointes (TdP). Pimozide is associated with a well-established risk of QT prolongation and TdP. Pitolisant prolongs the QT interval. [28225] [43463] [64562] Ponesimod: (Major) In general, do not initiate ponesimod in patients taking pitolisant due to the risk of additive bradycardia, QT prolongation, and torsade de pointes (TdP). If treatment initiation is considered, seek advice from a cardiologist. Ponesimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays. Ponesimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia. Pitolisant prolongs the QT interval. [64562] [66527] Posaconazole: (Major) Avoid coadministration of pitolisant with posaconazole as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Posaconazole has been associated with prolongation of the QT interval as well as rare cases of torsade de pointes. [32723] [64562] Primaquine: (Major) Avoid coadministration of pitolisant with primaquine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Primaquine has also been associated with QT interval prolongation. [41984] [64562] Primidone: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Procainamide: (Major) Avoid coadministration of pitolisant with procainamide as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Procainamide is associated with a well-established risk of QT prolongation and torsade de pointes (TdP). [28250] [64562] Prochlorperazine: (Minor) Prochlorperazine is associated with a possible risk for QT prolongation. Theoretically, prochlorperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation, such as pitolisant. [28415] [64562] Promethazine: (Major) Avoid coadministration of pitolisant with promethazine as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like promethazine, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. Promethazine, a phenothiazine, is associated with a possible risk for QT prolongation. [28225] [55578] [64562] Promethazine; Dextromethorphan: (Major) Avoid coadministration of pitolisant with promethazine as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like promethazine, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. Promethazine, a phenothiazine, is associated with a possible risk for QT prolongation. [28225] [55578] [64562] Promethazine; Phenylephrine: (Major) Avoid coadministration of pitolisant with promethazine as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like promethazine, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. Promethazine, a phenothiazine, is associated with a possible risk for QT prolongation. [28225] [55578] [64562] Propafenone: (Major) Concomitant use of propafenone and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28287] [64562] Protriptyline: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] QUEtiapine: (Major) Concomitant use of quetiapine and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [29118] [33068] [33072] [33074] [64562] quiNIDine: (Major) Concomitant use of pitolisant and quinidine increases the risk of QT/QTc prolongation and torsade de pointes (TdP) and may increase pitolisant exposure and the risk for other adverse effects. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. If concomitant use is necessary, reduce the pitolisant dosage by half for patients on a stable dose of pitolisant. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Additionally, consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring. Pitolisant is a CYP2D6 substrate, quinidine is a strong CYP2D6 inhibitor, and both medications have been associated with QT/QTc prolongation. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. [42280] [47357] [64562] quiNINE: (Major) Avoid coadministration of pitolisant with quinine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Quinine has been associated with QT prolongation and rare cases of torsade de pointes (TdP). [31403] [64562] Quizartinib: (Major) Concomitant use of quizartinib and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [64562] [69220] Ranolazine: (Major) Avoid coadministration of pitolisant with ranolazine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Ranolazine is associated with dose- and plasma concentration-related increases in the QTc interval. [31938] [64562] Relugolix: (Major) Avoid coadministration of pitolisant with relugolix as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Androgen deprivation therapy (i.e., relugolix) may also prolong the QT/QTc interval. [64562] [66183] Relugolix; Estradiol; Norethindrone acetate: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] (Major) Avoid coadministration of pitolisant with relugolix as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Androgen deprivation therapy (i.e., relugolix) may also prolong the QT/QTc interval. [64562] [66183] Revumenib: (Major) Concomitant use of revumenib and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [64562] [71540] Ribociclib: (Major) Avoid coadministration of pitolisant with ribociclib as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. The ribociclib ECG changes occurred within the first four weeks of treatment and were reversible with dose interruption. [61816] [64562] Ribociclib; Letrozole: (Major) Avoid coadministration of pitolisant with ribociclib as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. The ribociclib ECG changes occurred within the first four weeks of treatment and were reversible with dose interruption. [61816] [64562] rifAMPin: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with rifampin is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and rifampin is a strong CYP3A inducer. Concomitant use reduced pitolisant overall exposure by 50%. [56579] [64562] Rifapentine: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with rifapentine is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and rifapentine is a strong CYP3A inducer. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28483] [64562] Rilpivirine: (Major) Avoid coadministration of pitolisant with rilpivirine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. [44376] [64562] risperiDONE: (Major) Avoid coadministration of pitolisant with risperidone as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Risperidone has been associated with a possible risk for QT prolongation and/or TdP, primarily in the overdose setting. [28225] [28414] [64562] Ritonavir: (Moderate) Monitor for decreased efficacy of ritonavir if coadministered with pitolisant. Concurrent use may decrease the plasma concentrations of ritonavir leading to a reduction of antiretroviral efficacy and the potential development of viral resistance. Ritonavir is a CYP3A substrate and pitolisant is a weak CYP3A inducer. [64562] [67203] romiDEPsin: (Major) Avoid coadministration of pitolisant with romidepsin as concurrent use may increase the risk of QT prolongation. If concomitant use is necessary, consider monitoring electrolytes and ECGs at baseline and periodically during treatment. Pitolisant prolongs the QT interval. Romidepsin has been reported to prolong the QT interval. [37292] [64562] Saquinavir: (Major) Avoid coadministration of pitolisant with saquinavir/ritonavir as concurrent use may increase the risk of QT prolongation. If no acceptable alternative therapy is available, perform a baseline ECG prior to initiation of concomitant therapy and carefully follow monitoring recommendations. Pitolisant prolongs the QT interval. Saquinavir boosted with ritonavir increases the QT interval in a dose-dependent fashion, which may increase the risk for serious arrhythmias such as torsade de pointes (TdP). [28995] [64562] Secobarbital: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with barbiturates is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and barbiturates are strong CYP3A inducers. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [28596] [41911] [49229] [49236] [49352] [57046] [64562] Segesterone Acetate; Ethinyl Estradiol: (Major) Advise patients to use an alternative, non-hormonal contraceptive during and for at least 21 days after discontinuation of pitolisant. Pitolisant is a weak CYP3A4 inducer and may decrease the plasma exposure of hormonal contraceptives resulting in decreased efficacy. [64562] Selpercatinib: (Major) Avoid coadministration of pitolisant with selpercatinib as concurrent use may increase the risk of QT prolongation. Monitor ECGs more frequently for QT prolongation if coadministration is necessary. Pitolisant prolongs the QT interval. Concentration-dependent QT prolongation has been observed with selpercatinib therapy. [64562] [65387] Sertraline: (Major) Concomitant use of sertraline and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. The degree of QT prolongation associated with sertraline is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 2 times the maximum recommended dose. [28343] [64391] [64392] [64394] [64395] [64396] [64562] Sevoflurane: (Major) Avoid coadministration of pitolisant with halogenated anesthetics as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Halogenated anesthetics can also prolong the QT interval. [28457] [28458] [28754] [28755] [28756] [64562] Siponimod: (Major) Avoid coadministration of pitolisant with siponimod as concurrent use may increase the risk of QT prolongation. Consult a cardiologist regarding appropriate monitoring if siponimod use is required. Siponimod therapy prolonged the QT interval at recommended doses in a clinical study. Pitolisant prolongs the QT interval. [64031] [64562] Sirolimus: (Moderate) Monitor sirolimus concentrations and adjust sirolimus dosage as appropriate during concomitant use of pitolisant. Concomitant use may decrease sirolimus exposure and efficacy. Sirolimus is a CYP3A substrate and pitolisant is a weak CYP3A inducer. [28610] [64562] Sodium Stibogluconate: (Major) Concomitant use of sodium stibogluconate and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [64562] [64608] Solifenacin: (Major) Avoid coadministration of pitolisant with solifenacin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Solifenacin has been associated with dose-dependent prolongation of the QT interval. Torsade de pointes (TdP) has been reported with postmarketing use, although causality was not determined. [30515] [64562] SORAfenib: (Major) Avoid coadministration of sorafenib with pitolisant due to the risk of additive QT prolongation. Sorafenib is associated with QTc prolongation. Pitolisant also prolongs the QT interval. [31832] [64562] Sotalol: (Major) Concomitant use of sotalol and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28234] [64562] St. John's Wort, Hypericum perforatum: (Major) For patients on a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, double the original daily dose of pitolisant (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days if concurrent use with St. John's wort is necessary. Concomitant use may decrease pitolisant exposure which may reduce its efficacy. Pitolisant is a CYP3A substrate and St. John's wort is a strong CYP3A inducer. Concomitant use with another strong CYP3A inducer reduced pitolisant overall exposure by 50%. [56579] [64562] SUNItinib: (Major) Avoid coadministration of pitolisant with sunitinib as concurrent use may increase the risk of QT prolongation. If concomitant use is necessary, monitor for evidence of QT prolongation. Pitolisant prolongs the QT interval. Sunitinib can also prolong the QT interval. [31970] [64562] Tacrolimus: (Major) Avoid coadministration of pitolisant with tacrolimus as concurrent use may increase the risk of QT prolongation. If concomitant use is necessary, consider ECG and electrolyte monitoring periodically during treatment. Pitolisant prolongs the QT interval. Tacrolimus may also prolong the QT interval and cause torsade de pointes (TdP). [28611] [55401] [60497] [64562] Tamoxifen: (Major) Concomitant use of tamoxifen and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [61870] [61871] [61872] [63589] [64562] Telavancin: (Major) Avoid coadministration of pitolisant with telavancin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Telavancin has been associated with QT prolongation. [36615] [64562] Terbinafine: (Major) A pitolisant dosage reduction may be required during concomitant terbinafine use. For patients on a stable dose of pitolisant, reduce the pitolisant dosage by half. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Concomitant use may increase pitolisant exposure and the risk for pitolisant-related adverse effects. Pitolisant is a CYP2D6 substrate and terbinafine is a strong CYP2D6 inhibitor. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. [29840] [64562] Tetrabenazine: (Major) Avoid coadministration of pitolisant with tetrabenazine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Tetrabenazine causes a small increase in the corrected QT interval (QTc). [34389] [64562] Thioridazine: (Contraindicated) Coadministration of thioridazine with pitolisant is contraindicated due to the potential for QT prolongation and torsade de pointes (TdP). Thioridazine is associated with a well-established risk of QT prolongation and TdP. Pitolisant prolongs the QT interval. [28225] [28293] [64562] Tipranavir: (Major) A pitolisant dosage reduction may be required during concomitant tipranavir use. For patients on a stable dose of pitolisant, reduce the pitolisant dosage by half. For patients starting pitolisant, reduce the maximum recommended dosage by half to 17.8 mg once daily for adults and patients 6 years and older weighing 40 kg or more or 8.9 mg once daily for patients 6 years and older weighing less than 40 kg. Concomitant use may increase pitolisant exposure and the risk for pitolisant-related adverse effects. Pitolisant is a CYP2D6 substrate and tipranavir is a strong CYP2D6 inhibitor. Concomitant use with another strong CYP2D6 inhibitor increased pitolisant overall exposure by 2.2-fold. [31320] [64562] Tolterodine: (Major) Avoid coadministration of pitolisant with tolterodine as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Tolterodine has been associated with dose-dependent prolongation of the QT interval, especially in poor CYP2D6 metabolizers. [31112] [64562] Toremifene: (Major) Avoid coadministration of pitolisant with toremifene as concurrent use may increase the risk of QT prolongation. If concomitant use is unavoidable, closely monitor ECGs and electrolytes. Toremifene has been shown to prolong the QTc interval in a dose- and concentration-related manner. Pitolisant prolongs the QT interval. [28822] [64562] traMADol: (Moderate) Monitor for reduced efficacy of tramadol and signs of opioid withdrawal if coadministration with pitolisant is necessary; consider increasing the dose of tramadol as needed. If pitolisant is discontinued, consider a dose reduction of tramadol and frequently monitor for seizures, serotonin syndrome, and signs of respiratory depression and sedation. Tramadol is a CYP3A substrate and pitolisant is a weak CYP3A inducer. Concomitant use with CYP3A inducers can decrease tramadol levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. [32475] [40255] [51440] [64562] Tramadol; Acetaminophen: (Moderate) Monitor for reduced efficacy of tramadol and signs of opioid withdrawal if coadministration with pitolisant is necessary; consider increasing the dose of tramadol as needed. If pitolisant is discontinued, consider a dose reduction of tramadol and frequently monitor for seizures, serotonin syndrome, and signs of respiratory depression and sedation. Tramadol is a CYP3A substrate and pitolisant is a weak CYP3A inducer. Concomitant use with CYP3A inducers can decrease tramadol levels; this may result in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence. [32475] [40255] [51440] [64562] traZODone: (Major) Concomitant use of trazodone and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [38831] [64562] Triclabendazole: (Major) Concomitant use of triclabendazole and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [63962] [64562] Tricyclic antidepressants: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] Trifluoperazine: (Minor) Trifluoperazine is associated with a possible risk for QT prolongation. Theoretically, trifluoperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation, such as pitolisant. [28415] [64562] Trimipramine: (Major) Avoid coadministration of pitolisant with tricyclic antidepressants (TCAs) as the effect of pitolisant may be decreased; concurrent use may also increase the risk of QT prolongation. Pitolisant increases histamine concentrations in the brain; therefore, H1-receptor antagonists like TCAs, may reduce pitolisant efficacy. Pitolisant prolongs the QT interval. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [64562] Triptorelin: (Major) Avoid coadministration of pitolisant with triptorelin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Androgen deprivation therapy (i.e., triptorelin) may prolong the QT/QTc interval. [45411] [64562] Vandetanib: (Major) Avoid coadministration of vandetanib with pitolisant due to an increased risk of QT prolongation and torsade de pointes (TdP). If concomitant use is unavoidable, monitor ECGs for QT prolongation and monitor electrolytes; correct hypocalcemia, hypomagnesemia, and/or hypomagnesemia prior to vandetanib administration. An interruption of vandetanib therapy or dose reduction may be necessary for QT prolongation. Vandetanib can prolong the QT interval in a concentration-dependent manner; TdP and sudden death have been reported in patients receiving vandetanib. Pitolisant prolongs the QT interval. [43901] [64562] Vardenafil: (Major) Concomitant use of vardenafil and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [28216] [64562] Vemurafenib: (Major) Avoid coadministration of pitolisant with vemurafenib as concurrent use may increase the risk of QT prolongation. If coadministration is necessary, monitor ECG. Pitolisant prolongs the QT interval. Vemurafenib has also been associated with QT prolongation. [45335] [64562] Venlafaxine: (Major) Concomitant use of venlafaxine and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. [33715] [64562] Voclosporin: (Major) Avoid concomitant use of pitolisant and voclosporin due to the risk of additive QT prolongation. Pitolisant prolongs the QT interval. Voclosporin has been associated with QT prolongation at supratherapeutic doses. [64562] [66336] Vonoprazan; Amoxicillin; Clarithromycin: (Major) Avoid coadministration of pitolisant with clarithromycin as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Clarithromycin is associated with an established risk for QT prolongation and torsade de pointes (TdP). [28225] [28238] [64562] Voriconazole: (Major) Avoid coadministration of pitolisant with voriconazole as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Voriconazole has been associated with QT prolongation and rare cases of torsade de pointes. [28158] [64562] Vorinostat: (Major) Avoid coadministration of pitolisant with vorinostat as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Vorinostat therapy is also associated with a risk of QT prolongation. [32789] [64562] Warfarin: (Moderate) Closely monitor the INR if coadministration of warfarin with pitolisant is necessary as concurrent use may decrease the exposure of warfarin leading to reduced efficacy. Pitolisant is a weak CYP3A4 inducer and the R-enantiomer of warfarin is a CYP3A4 substrate. The S-enantiomer of warfarin exhibits 2 to 5 times more anticoagulant activity than the R-enantiomer, but the R-enantiomer generally has a slower clearance. [28549] [64562] Ziprasidone: (Major) Avoid coadministration of pitolisant with ziprasidone as concurrent use may increase the risk of QT prolongation. Pitolisant prolongs the QT interval. Clinical trial data indicate that ziprasidone causes QT prolongation; there are postmarketing reports of torsade de pointes (TdP) in patients with multiple confounding factors. [28233] [64562]
        Revision Date: 12/05/2024, 02:07:00 AM

        References

        23500 - Wilt JL, Minnema AM, Johnson RF, et al. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993;119:391-4.23620 - Green PT, Reents S, Harman E, et al. Pentamidine-induced torsades de pointes in a renal tranplant recipient with Pneumocystis carinii pneumonia. S Med J 1990;83:481-4.23774 - Lui HK, Lee G, Dietrich P, et al. Flecainide-induced QT prolongation and ventricular tachycardia. Am Heart J 1982;103:567-9.23778 - Wharton JM, Demopulos PA, Goldschlager N. Torsade de pointes during administration of pentamidine isethionate. Am J Med 1987;83:571-6.23779 - Kriwisky M, Perry GY, Tarchitsky D, et al. Haloperidol-induced torsades de pointes. Chest 1990;98:482-3.27982 - Ketoconazole tablets package insert. Morgantown, WV: Mylan Pharmaceuticals, Inc.; 2017 Sept.28158 - VFEND (voriconazole) tablets, suspension, and injection package insert. New York, NY: Pfizer Inc; 2024 Aug.28216 - Levitra (vardenafil) package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2023 Mar.28221 - Tikosyn (dofetilide) package insert. New York, NY: Pfizer Labs; 2019 Aug.28224 - Pacerone (amiodarone) tablets package insert. Maple Grove, MN: Upsher-Smith Laboratories, LLC.; 2018 Nov.28225 - CredibleMeds. Drugs to avoid in congenital long QT. Available on the World Wide Web at http://www.crediblemeds.org.28228 - Norpace and Norpace CR (disopyramide) package insert. Chicago, IL: G.D. Searle LLC division of Pfizer Inc; 2016 Aug.28229 - Demaziere J, Fourcade JM, Busseuil CT, et al. The hazards of chloroquine self prescription in west Africa. J Toxicol Clin Toxicol 1995;33:369-70.28230 - Mansfield RJ, Thomas RD. Recurrent syncope. Drug induced long QT syndrome. Postgrad Med J 2001;77:344, 352-3.28231 - Pinski SL, Eguia LE, Trohman RG. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 2002;25:1612-5.28233 - Geodon (ziprasidone) package insert. New York, NY: Pfizer: 2021 May.28234 - Betapace (sotalol) package insert. Wayne, NJ: Berlex Laboratories; 2011 Aug.28235 - Richards JR, Schneir AB. Droperidol in the emergency department: is it safe? J Emerg Med 2003;24:441-7.28236 - Kao LW, Kirk MA, Evers SJ, et al. Droperidol, QT prolongation, and sudden death: what is the evidence? Ann Emerg Med 2003;41:546-58.28238 - Biaxin (clarithromycin) package insert. North Chicago, IL: AbbVie, Inc.; 2019 Sep.28250 - Procanbid (procainamide) package insert. Bristol, TN: Monarch Pharmaceuticals; 2002 Jan.28260 - Paxil (paroxetine) tablet and oral suspension package insert. Weston, FL: Apotex Corp.; 2024 Nov.28261 - Uroxatral (alfuzosin extended-release tablets) package insert. St. Michael, Barbados: Concordia Pharmaceuticals, INC.; 2015 May.28262 - Clozaril (clozapine) tablets package insert. Rosemont, PA: HLS Therapeutics (USA), Inc.; 2024 Sept.28269 - Celexa (citalopram) tablets package insert. North Chicago, IL: AbbVie Inc.; 2023 Oct.28270 - Lexapro (escitalopram) package insert. North Chicago, IL: Abbvie, Inc.; 2024 Apr.28287 - Rythmol SR (propafenone hydrochloride) capsule extended release package insert. Research Triangle Park, NC: GlaxoSmithKline; 2018 Nov.28293 - Thioridazine package insert. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2016 Nov.28301 - Mefloquine hydrochloride package insert. North Wales PA: Teva Pharmaceuticals USA Inc.; 2019 Mar.28307 - Haldol (haloperidol) injection for immediate release package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2020 Feb.28308 - Anzemet (dolasetron mesylate) tablets package insert. Parsippany, NJ: Validus Pharmaceuticals LLC; 2021 June.28319 - Krantz MJ, Kutinsky IB, Robertson AD, et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802-5.28320 - Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003;103:321-4.28321 - Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506.28322 - Gil M, Sala M, Anguera I, et al. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003;92:995-7.28341 - Kaletra (lopinavir; ritonavir) tablet and solution package insert. North Chicago, IL: AbbVie Inc; 2020 Oct.28343 - Zoloft (sertraline) package insert. Morgantown, WV: Viatris Specialty LLC; 2023 Aug.28377 - Foscavir (foscarnet) package insert. Lake Forest, IL: Hospira, Inc.; 2020 Oct.28405 - Strattera (atomoxetine) package insert. Indianapolis, IN: Eli Lilly and Company; 2022 Jan.28414 - Risperdal (risperidone tablets, oral solution, and orally disintegrating tablets) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2022 Aug.28415 - Nora Goldschlager, Andrew E Epstein, Blair P Grubb, et al. Etiologic considerations in the patient with syncope and an apparently normal heart. Arch Intern Med 2003;163:151-62.28416 - Hansten PD, Horn JR. Drug Interactions with Drugs that Increase QTc Intervals. In: The Top 100 Drug Interactions - A Guide to Patient Management. 2007 Edition. Freeland, WA: H&H Publications; 2007:144-8.28419 - Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001;21:301-19.28421 - Levaquin (levofloxacin) tablet package insert. Titusville, NJ: Janssen Pharmaceutical, Inc.; 2020 Jun.28423 - Avelox (moxifloxacin) package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2020 May.28424 - Factive (gemifloxacin mesylate) package insert. Toronto, ON: Merus Labs International, Inc.; 2019 May.28432 - Roden, DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004;350:1013-22.28442 - Sustiva (efavirenz) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2023 Nov.28457 - Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881-908.28458 - Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991;72:137-44.28483 - Priftin (rifapentine) package insert. Bridgewater, NJ: Sanofi-Aventis Pharmaceuticals Inc.; 2020 Jun.28549 - Coumadin (warfarin tablets) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2017 Aug.28592 - Zoladex (goserelin acetate 3.6 mg implant) package insert. Lake Forest, IL: TerSera Therapeutics LLC; 2023 March28596 - Phenobarbital tablets package insert. Fort Lauderdale, FL: ECI Pharmaceuticals, LLC; 2022 Aug.28610 - Rapamune (sirolimus) package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2022 Aug.28611 - Prograf (tacrolimus) capsules, injection, and granules for oral suspension package insert. Northbrook, IL: Astellas Pharma US, Inc.; 2023 Aug.28661 - Apokyn (apomorphine injection) package insert. Rockville, MD: MMD US Operations, LLC; 2022 Jun28674 - Diflucan oral tablet and suspension (fluconazole) package insert. New York, NY: Pfizer; 2024 Feb.28737 - Droperidol injection package insert. Shirley NY: American Regent, Inc. 2023 Mar.28752 - Thevenin J, Da Costa A, Roche F, et al. Flecainide induced ventricular tachycardia (torsades de pointes). Pacing Clin Electrophysiol 2003;26:1907-8.28754 - Loeckinger A, Kleinsasser A, Maier S, et al. Sustained prolongation of the QTc interval after anesthesia with sevoflurane in infants during the first 6 months of life. Anesthesiology 2003;98:639-42.28755 - Kleinsasser A, Loeckinger A, Lindner KH, et al. Reversing sevoflurane-associated Q-Tc prolongation by changing to propofol. Anaesthesia 2001;56:248-50.28756 - Kuenszberg E, Loeckinger A, Kleinsasser A, et al. Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000;17:662-4.28759 - Maprotiline HCl tablet package insert. Morgantown WV: Mylan Pharmaceuticals Inc; 2014 Dec.28785 - Zyprexa (olanzapine, all oral formulations and injectable solution) package insert. Indianapolis, IN: Eli Lilly and Company; 2020 Apr.28822 - Fareston (toremifene citrate) tablets package insert. Bedminster, NJ: Kyowa Kirin Inc.; 2017 May.28855 - Zithromax (azithromycin 250 mg and 500 mg tablets and azithromycin oral suspension) package insert. New York, NY: Pfizer Inc.; 2021 Nov.28879 - Pentamidine isethionate injection package insert. East Brunswick, NJ: Avet Pharmaceuticals Inc.; 2021 Jan.28978 - Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000;39:49-75.28995 - Invirase (saquinavir) package insert. South San Francisco, CA: Genentech Inc.; 2020 Sept.29118 - Seroquel (quetiapine fumarate) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022 Jan.29758 - Aralen (chloroquine) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC.; 2018 Oct.29833 - Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468-72.29840 - Madani S, Barilla, D, Cramer J, et al. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol 2002;42:1211-1218.30106 - Imodium A-D Liquid and Caplets (loperamide HCL) consumer product labels. Fort Washington, PA: Johnson and Johnson Consumer Inc., McNeil Consumer Healthcare Division; 2019.30163 - Agrylin (anagrelide) capsules package insert. Lexington, MA: Takeda Pharmaceuticals USA, Inc.; 2021 Oct.30369 - Vantas (histrelin implant) package insert. Chadds Ford, PA: Endo Pharmaceuticals Solutions Inc.; 2022 Feb.30515 - Vesicare (solifenacin) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2012 Jul.30738 - Ofloxacin tablets package insert. Sacramento, CA: Nivagen Pharmaceuticals, Inc.; 2019 Feb.31112 - Detrol (tolterodine tartrate) package insert. New York, NY: Pharmacia and Upjohn Co., division of Pfizer; 2016 Nov.31266 - Zofran (ondansetron) injection package insert. Research Triangle Park, NC: GlaxoSmithKline; 2021 Oct.31320 - Aptivus (tipranavir) package insert. Ridgefield, CT: Boehringer Ingelheim; 2024 Apr.31403 - Qualaquin (quinine sulfate) capsules package insert. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2019 Jun.31723 - Kytril injection (granisetron) package insert. Nutley, NJ: Roche Pharmaceuticals; 2011 Nov.31832 - Nexavar (sorafenib) package insert. Wayne, NJ; Bayer HealthCare Pharmaceuticals Inc.; 2020 July.31938 - Ranexa (ranolazine extended-release tablets) package insert. Foster City, CA: Gilead Sciences, Inc. 2019 Oct.31970 - Sunitinib (Sutent) package insert. New York, NY: Pfizer Labs; 2020 Aug.32061 - Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 2004;59:5-12.32062 - Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37.32387 - Sprycel (dasatinib) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2014 April.32475 - Tramadol hydrochloride extended-release tablets package insert. Baltimore, MD: Lupin Pharmaceuticals, Inc.; 2023 Sep.32723 - Noxafil (posaconazole) package insert. Rahway, NJ: Merck & Co. Inc.: 2024 Oct.32732 - Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005;20:243-51.32734 - Su KP, Lane HY, Chuang CL, et al. Olanzapine-induced QTc prolongation in a patient with wolff-parkinson-white syndrome. Schizophrenia Research 2004;66:191-2.32745 - Dineen S, Withrow K, Voronovitch L, et al. QTc prolongation and high-dose olanzapine. Psychosomatics 2003;44:174-5.32746 - Gurovich, I. QTc prolongation: chlorpromazine and high-dosage olanzapine. Can J Psychiatry 2003;48:348.32789 - Zolinza (vorinostat) capsules package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2018 Dec.33068 - Gajwani P, Pozuelo L, Tesar G, et al. QT interval prolongation associated with quetiapine (seroquel) overdose. Psychosomatics 2000;41:63-5.33072 - Beelen AP, Yeo KTJ, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001;20:215-9.33074 - Furst BA, Champion KM, Pierre JM, et al. Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biol Psychiatry 2002;51:264-5.33136 - Methadone hydrochloride tablets package insert. Webster Groves, MO: SpecGx LLC; 2024 Jan.33144 - Owens RC Jr, Ambrose PG. Antimicrobial Safety: Focus on fluoroquinolones. Clin Infect Dis 2005;41 (Suppl 2):S144-S157.33145 - Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007;doi:10.1016/j.ijantimicag.2006.11.01133146 - Bischoff U, Schmidt C, Netzer R, et al. Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 2000;406:341-3.33192 - Tykerb (lapatinib) tablet package insert. Research Triangle Park, NC: GlaxoSmithKline; 2022 March.33715 - Effexor XR (venlafaxine extended-release capsules) package insert. Morgatown, WV: Viatris Specialty LLC; 2023 Aug.34389 - Xenazine (tetrabenazine) package insert. Deerfield, IL: Lundbeck, Inc.; 2017 Sep.35401 - Coartem (artemether; lumefantrine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019 Aug.36101 - Multaq (dronedarone) package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2023 Oct.36146 - Fanapt (iloperidone) package insert. Washington, DC: Vanda Pharmaceuticals, Inc.; 2024 Apr.36343 - Saphris (asenapine) sublingual tablet package insert. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2017 Mar.36615 - Vibativ (telavancin) package insert. Nashville, TN: Cumberland Pharmaceuticals Inc.; 2020 July.36894 - Metronidazole injection package insert. Deerfield, IL: Baxter Healthcare Corporation; 2024 July.37098 - Votrient (pazopanib) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2011 Oct.37292 - Istodax (romidepsin) injection package insert. Summit, NJ: Celgene Corporation; 2021 July.38831 - Oleptro (trazodone hydrochloride) extended-release tablets package insert. Dublin, Ireland: Labopharm Europe Limited; 2014 Jul.40233 - Sporanox (itraconazole) oral solution package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2024 Oct.40255 - Rybix ODT (tramadol) package insert. San Diego, CA: Victory Pharma, Inc.; 2009 Dec.40936 - Invega Sustenna (paliperidone palmitate injectable suspension) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2024 Sept.40942 - Remeron and Remeron SolTabs (mirtazapine tablets and ODT tablets) package insert. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2021 Nov.41057 - Wellbutrin XL (bupropion) package insert. Bridgewater, NJ: Bausch Health US, LLC; 2024 Mar.41235 - Butrans (buprenorphine transdermal system) package insert. Stamford, CT: Purdue Pharma L.P.; 2023 Dec.41237 - Tegretol (carbamazepine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023 Sep.41806 - Plaquenil (hydroxychloroquine) package insert. Dublin, Ireland: Amdipharm Limited; 2023 Dec.41823 - Gilenya (fingolimod) package insert. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2024 Jun.41830 - Corvert (ibutilide) package insert. New York, NY: Pharmacia and Upjohn Company; 2023 Nov.41911 - Brevital (methohexital) package insert. Chestnut Ridge, NY: Par Pharmaceutical; 2020 Oct.41934 - Lysodren (mitotane) package insert. Sermoneta, Italy: Latin Pharma S.p.A.; 2024 Oct.41958 - Eloxatin (oxaliplatin) package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC; 2023 June.41984 - Primaquine phosphate package insert. Bridgewater, NJ: Sanofi-aventis; 2017 Jun.42280 - Nuedexta (dextromethorphan hydrobromide; quinidine sulfate capsule) package insert. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; 2019 Jun.42449 - Halaven (eribulin mesylate) injection package insert. Woodcliffe Lake, NJ: Eisai Inc.; 2022 Sept.42845 - Abilify (aripiprazole) tablets, discmelt orally-disintegrating tablets, oral solution, and intramuscular injection package insert. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2022 Nov.43065 - Chlorpromazine package insert. Princeton, NJ: Sandoz Inc; 2019 Dec.43258 - Eryped (erythromycin ethylsuccinate) package insert. Atlanta, GA: Arbor Pharmaceuticals, INC.; 2018 Apr.43411 - Cipro (ciprofloxacin tablet; suspension) package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2024 Sept.43463 - Pimozide tablets package insert. Chestnut Ridge, NY: Par Pharmaceuticals; 2017 March.43901 - Caprelsa (vandetanib) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024 March.43974 - Zithromax (azithromycin injection) package insert. New York, NY: Pfizer Inc.; 2021 Nov.44058 - Prozac Weekly (fluoxetine hydrochloride delayed-release capsules) package insert. Indianapolis, IN: Lilly USA, LLC; 2017 Mar.44376 - Edurant (rilpivirine) package insert. Titusville, NJ: Janssen Therapeutics; 2024 Mar.45335 - Zelboraf (vemurafenib) tablet package insert. South San Francisco, CA: Genentech USA, Inc.; 2020 May.45411 - Trelstar (triptorelin pamoate for injectable suspension) package insert. Ewing, NJ: Verity Pharmaceuticals, Inc.; 2024 April.45458 - Xalkori (crizotinib) capsules and pellets package insert. New York, NY: Pfizer Labs; 2023 Sept.46869 - Firmagon (degarelix) package insert. Parsippany, NJ: Ferring Pharmaceuticals Inc.; 2020 Dec.47129 - Hydroxyzine hydrochloride injection package insert. Miami, FL: Atlantic Biologicals Corp; 2019 Sept.47221 - Propulsid (cisapride) package insert. Titusville, NJ; Janssen Pharmaceutica; 2006 Oct. NOTE: As of May 2000; Propulsid has only been available in the United States via an investigational limited access program to ensure proper patient screening and prescribing.47357 - Quinidine gluconate extended-release tablet package insert. Princeton, NJ: Eywa Pharma Inc.; 2021 Dec.48697 - Korlym (mifepristone) tablet package insert. Menlo Park, CA: Corcept Therapeutics; 2019 Nov.48869 - Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and tosade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011;120:103-10.48871 - Bril Fernando, Gonzalez CD, Di Girolamo G. Antimicrobial agents-associated with QT interval prolongation. Curr Drug Saf 2010;5:85-92.49229 - Amytal (amobarbital sodium) package insert. Bridgewater, NJ: Bausch Health US, LLC; 2020 Jul.49236 - Butisol (butabarbital sodium) tablet and solution package insert. Somerset, NJ; Meda Pharmaceuticals, Inc.; 2018 Dec.49352 - Seconal (secobarbital sodium) capsules package insert. Jacksonville, Fl: Ranbaxy Pharmaceuticals, Inc.; 2008 Sept.50275 - Anzemet (dolasetron mesylate) injection package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2014 Sept.50507 - Luvox CR (fluvoxamine maleate extended-release capsules) package insert. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2017 Jan.51289 - Droperidol injection package insert. Shirley NY: American Regent, Inc. 2023 Mar.51440 - Conzip (tramadol hydrochloride extended-release capsules) package insert. Alpharetta, GA: Vertical Pharmaceuticals LLC; 2023 Dec.51727 - Xtandi (enzalutamide) capsule and tablet package insert. Northbrook, IL:Astellas Pharma US, Inc.; 2023 Nov.52611 - Signifor (pasireotide diaspartate) package insert. Stein, Switzerland: Novartis Pharma Stein AG; 2024 July.52746 - Sirturo (bedaquiline) tablets package insert. Horsham, PA: Janssen Products, LP; 2024 Jun.53347 - DeVane CL, Donovan JL, Liston HL, et al. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004;24:4-10.55401 - Astagraf XL (tacrolimus extended-release capsules) package insert. Northbrook, IL: Astellas Pharma US, Inc.; 2023 Aug.55578 - Owczuk R, Twardowski P, Dylczyk-Sommer A, et al. Influence of promethazine on cardiac repolarization: a double-blind, midazolam-controlled study. Anaesthesia 2009;64:609-614.56579 - U.S. Food and Drug Administration (FDA). For Healthcare Professionals: FDA's Examples of Drugs that Interact with CYP Enzymes and Transporter Systems. Retrieved Aug 2024. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems57046 - Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-10.57094 - Zykadia (ceritinib) package insert. Indianapolis, IN: Novartis; 2021 Oct.57441 - Iribarren C, Round AD, Peng JA, et al. Validation of a population-based method to assess drug-induced alterations in QT interval: a self-controlled crossover study. Pharmacoepidemiol Drug Saf 2013;22;1222-32.57803 - Cerdelga (eliglustat) capsules. Waterford, Ireland: Genzyme Ireland, Ltd.;2018 Sept.58766 - Tasigna (nilotinib) capsules package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024 Feb.58782 - Lenvima (lenvatinib) package insert. Woodcliff Lake, NJ:Eisai Inc; 2024 June.58821 - Farydak (panobinostat) capsules package insert. Las Vegas, NV: Secura Bio, Inc.; 2021 Sept.59321 - CredibleMeds. QT drug lists. Available on the World Wide Web at http://www.crediblemeds.org.59322 - Howes LG. Cardiovascular effects of drugs used to treat alzheimer's disease. Drug Saf. 2014;37:391–395.59438 - Trisenox (arsenic trioxide) injection package insert. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; 2020 Oct.59809 - Mamiya K, Sadanaga T, Sekita A, et al. Lithium concentration correlates with QTc in patients with psychosis. J Electrocardiol 2005;38:148-51.59810 - van Noord C, Straus SM, Sturkenboom MC, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 2009;29:9-15.59811 - Altinbas K, Guloksuz S, Caglar IM, et al. Electrocardiography changes in bipolar patients during long-term lithium monotherapy. Gen Hosp Psychiatry 2014;36:694-7.59891 - Orkambi (lumacaftor; ivacaftor) tablet package insert. Boston, MA: Vertex Pharmaceuticals, Inc. 2024 Dec60164 - Vraylar (cariprazine capsules) package insert. North Chicago, IL:AbbVie, Inc.; 2024 Nov.60270 - Belbuca (buprenorphine) buccal film package insert. BioDeliviery Sciences International, Inc.: Raleigh, NC; 2023 Dec.60297 - Tagrisso (osimertinib) tablet package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024 Sept.60497 - Envarsus XR (tacrolimus) extended-release tablets. Cary, NC: Veloxis Pharmaceuticals, Inc.; 2024 Apr.60748 - Nuplazid (pimavanserin) package insert. San Diego, CA: Acadia; 2023 Sept.60864 - US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Retrieved June 7, 2016. Available on the World Wide Web at: http://www.fda.gov/Drugs/DrugSafety/ucm504617.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery61816 - Kisqali (ribociclib) tablets package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024 Sept.61845 - Austedo and Austedo XR (deutetrabenazine) tablets and extended-release tablets package insert. Parsippany, NJ: Teva Neuroscience, Inc.; 2024 Jul.61870 - Chiu MH, Al-Majed NS, Stubbins R, et al. A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use. BMC Res Notes. 2016;9:310.61871 - Slovacek L, Priester P, Petera J, et al. Tamoxifen/norfloxacin interaction leading to QT interval prolongation in a female patient with extracranial meningioma. Bratisl Lek Listy. 2011;112(6):353-4.61872 - Slovacek L, Ansorgova V, Macingova Z, et al. Tamoxifen-induced QT interval prolongation. J Clin Pharm Ther. 2008;33(4):453-5.61906 - Rydapt (midostaurin) capsule package insert. East Hanover,NJ: Novartis Pharmaceuticals Corporation; 2023 May.62245 - Besponsa (inotuzumab ozogamicin) injection package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2024 Mar.62292 - Mylotarg (gemtuzumab ozogamicin) injection package insert. Philadelphia, PA: Pfizer Inc.; 2020 Feb.62723 - Macrilen (macimorelin) package insert. Frankfurt am Main, Germany: Aeterna Zentaris GmbH; 2018 Jan.62874 - Erleada (apalutamide) tablets package insert. Horsham, PA: Janssen Products, LP; 2024 Aug.63161 - Lucemyra (lofexidine) tablets package insert. Louisville, KY: US WorldMeds, LLC; 2018 May.63317 - Braftovi (encorafenib) capsules package insert. Boulder, CO: Array BioPharma Inc.; 2024 Sep.63368 - Tibsovo (ivosidenib) tablet package insert. Cambridge, MA: Agios Pharmaceuticals; 2023 Oct.63584 - Vizimpro (dacomitinib) tablet package insert. New York, NY: Pfizer Labs; 2018 Sept.63589 - Soltamox (tamoxifen) oral solution package insert. Raleigh, NC: Midatech Pharma US Inc.; 2019 April.63777 - Daurismo (glasdegib) tablets package insert. New York, NY: Pfizer Labs; 2023 Mar.63787 - Xospata (gilteritinib) tablets package insert. Northbrook, IL: Astellas Pharma US, Inc.; 2022 Jan.63936 - Lamprene (clofazimine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019 Jan.63962 - Egaten (triclabendazole) package insert. East Hanover, NJ: Novartis Pharmaceuticals; 2022 Feb.64031 - Mayzent (siponimod) tablets package insert. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2024 Jun.64391 - Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014;75:e441-e449.64392 - Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-709.64394 - O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010;56:692-699.64395 - Brouillette J, Nattel S. A practical approach to avoiding cardiovascular adverse effects of psychoactive medications. Can J Cardiol 2017;33:1577-1586.64396 - Beach SR, Celano CM, Sugrue AM, et al. QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update. Psychosomatics 2018;59:105-122.64562 - Wakix (pitolisant) tablets package insert. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2024 Jun.64567 - Rozlytrek (entrectinib) package insert. South San Francisco, CA: Genentech Inc.; 2024 Jan.64576 - Xenleta (lefamulin) package insert. Dublin, Ireland: Nabriva Therapeutics US, Inc.; 2021 Mar.64608 - Pentostam (sodium stibogluconate injection) package leaflet: Information for the healthcare professional. Middlesex, United Kingdom: GlaxoSmithKline UK; 2014 Feb.64885 - Caplyta (lumateperone) capsules package insert. New York, NY; Intra-Cellular Therapies, Inc.; 2023 Jun.65068 - Barhemsys (amisulpride) package insert. Indianapolis, IN: Acacia Pharma Inc; 2021 May.65098 - Isturisa (osilodrostat) tablet package insert. Lebanon, NJ: Recordati Rare Disease, Inc.; 2020 Mar.65157 - CredibleMeds. COVID-19 experimental therapies and TdP risk. Available on the World Wide Web at http://https://crediblemeds.org/blog/covid-19-experimental-therapies-and-tdp-risk. Accessed March 23, 2020.65169 - Ozanimod (Zeposia) capsules package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2024 Aug.65170 - Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19 [published online ahead of print, March 25, 2020]. Mayo Clin Proc 2020;95.65387 - Retevmo (selpercatinib) capsules and tablets package insert. Indianapolis, IN: Eli Lilly and Company; 2024 Sept.65666 - Rukobia (fostemsavir) package insert. Durham, NC: ViiV Healthcare; 2024 Feb.66183 - Orgovyx (relugolix) tablets package insert. Brisbane, CA: Myovant Sciences, Inc.; 2024 Oct.66336 - Lupkynis (voclosporin) capsules package insert. Rockville, MD: Aurinia Pharma U.S., Inc.; 2024 Apr.66527 - Ponvory (ponesimod) tablet package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2024 Jun.66812 - Fexinidazole package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2024 Sept.66990 - Exkivity (mobocertinib) capsules package insert. Lexington, MA: Takeda Pharmaceuticals America, Inc.; 2023 Sept.67011 - Qulipta (atogepant) tablet package insert. Dublin, Ireland: Forest Laboratories Ireland Ltd.; 2023 Apr.67136 - Fyarro (sirolimus protein-bound particles) injectable suspension package insert. Pacific Palisades, CA: Aadi Bioscience, Inc.; 2021 Nov.67203 - Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for Paxlovid. Retrieved March 13, 2024. Available on the World Wide Web at https://www.fda.gov/media/155050/download?utm_medium=email&utm_source=govdelivery67231 - Recorlev (levoketoconazole) package insert. Chicago, IL: Xeris Pharmaceuticals, Inc.; 2021 Dec.67427 - Vonjo (pacritinib) capsules package insert. Seattle, WA: CTI BioPharma Corp; 2024 Nov.67509 - Igalmi (dexmedetomidine) sublingual film package insert. New Haven, CT: BioXcel Therapeutics, Inc.; 2022 Apr.68325 - Krazati (adagrasib) tablets package insert. San Diego, CA: Mirati Therapeutics, Inc.; 2024 June.69114 - Velsipity (etrasimod) package insert. New York, NY: Pfizer, Inc.; 2024 Jun.69220 - Vanflyta (quizartinib) tablets package insert. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2024 July.70477 - Duvyzat (givinostat) oral suspension package insert. Concord, MA: ITF Therapeutics, LLC; 2024 March70577 - Xolremdi (mavorixafor) capsules package insert. Boston, MA: X4 Pharmaceuticals, Inc.; 2024 Apr.71540 - Revuforj (revumenib) tablets package insert. Waltham, MA: Syndax Pharmaceuticals, Inc.; Nov 2024.

        Monitoring Parameters

        • LFTs
        • serum bilirubin
        • serum creatinine/BUN

        US Drug Names

        • Wakix
        Small Elsevier Logo

        Cookies are used by this site. To decline or learn more, visit our cookie notice.


        Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

        Small Elsevier Logo
        RELX Group